PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
17876882-8	2007	CS could attenuate the up-regulation of the Chiu"s score, the levels of MDA, TNF-alpha, and expression of tryptase and the down-regulation of SOD activity and histamine concentration.	Cromolyn Sodium	0-2	tumor necrosis factor	Rattus norvegicus	77-86
19304545-0	2009	[Role of sodium cromoglycate in brain protection and its effects on tumor necrosis factor-alpha and interleukin-1beta after global cerebral ischemia-reperfusion injury in gerbils].	Cromolyn Sodium	9-28	tumor necrosis factor	Homo sapiens	68-95
19304545-0	2009	[Role of sodium cromoglycate in brain protection and its effects on tumor necrosis factor-alpha and interleukin-1beta after global cerebral ischemia-reperfusion injury in gerbils].	Cromolyn Sodium	9-28	interleukin 1 beta	Homo sapiens	100-117
19304545-1	2009	OBJECTIVE: To investigate the role of sodium cromoglycate in brain protection and its effects on brain tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) expressions after global cerebral ischemia-reperfusion (IR) injury in gerbils.	Cromolyn Sodium	38-57	tumor necrosis factor	Homo sapiens	103-130
19304545-1	2009	OBJECTIVE: To investigate the role of sodium cromoglycate in brain protection and its effects on brain tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) expressions after global cerebral ischemia-reperfusion (IR) injury in gerbils.	Cromolyn Sodium	38-57	tumor necrosis factor	Homo sapiens	132-141
19304545-1	2009	OBJECTIVE: To investigate the role of sodium cromoglycate in brain protection and its effects on brain tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) expressions after global cerebral ischemia-reperfusion (IR) injury in gerbils.	Cromolyn Sodium	38-57	interleukin 1 beta	Homo sapiens	147-164
19304545-1	2009	OBJECTIVE: To investigate the role of sodium cromoglycate in brain protection and its effects on brain tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) expressions after global cerebral ischemia-reperfusion (IR) injury in gerbils.	Cromolyn Sodium	38-57	interleukin 1 beta	Homo sapiens	166-174
19304545-8	2009	The brain TNF-alpha and IL-1beta levels in sodium cromoglycate group were significantly decreased as compared with those in the model group (P<0.05).	Cromolyn Sodium	43-62	tumor necrosis factor	Homo sapiens	10-19
19304545-8	2009	The brain TNF-alpha and IL-1beta levels in sodium cromoglycate group were significantly decreased as compared with those in the model group (P<0.05).	Cromolyn Sodium	43-62	interleukin 1 beta	Homo sapiens	24-32
19304545-9	2009	CONCLUSION: Sodium cromoglycate can alleviate brain IR injury possibly by lowering the TNF-alpha and IL-1beta levels in the brain tissues.	Cromolyn Sodium	12-31	tumor necrosis factor	Homo sapiens	87-96
19304545-9	2009	CONCLUSION: Sodium cromoglycate can alleviate brain IR injury possibly by lowering the TNF-alpha and IL-1beta levels in the brain tissues.	Cromolyn Sodium	12-31	interleukin 1 beta	Homo sapiens	101-109
19073601-10	2009	Cromolyn, which inhibits the binding of S100P to its receptor, enhanced the celecoxib-mediated inhibition of cell invasion and growth but did not affect apoptosis.	Cromolyn Sodium	0-8	S100 calcium binding protein P	Homo sapiens	40-45
18788466-6	2008	Disodium cromoglycate treatment inhibited the HSD40-induced elevations in myocardial contractility and MC degranulation, and similar hemodynamic changes were noted after treatment with ETR-p1/fl peptide, together with a normalized myocardial myocardial ET-1 content, NO synthesis and a significant reduction in MC degranulation.	Cromolyn Sodium	0-21	endothelin 1	Canis lupus familiaris	253-257
18162498-4	2008	Topical sodium cromolyn was applied twice a day to atrophic areas and prophylactically to new sites of insulin administration.	Cromolyn Sodium	8-23	insulin	Homo sapiens	103-110
18162498-7	2008	CONCLUSIONS: Tryptase-positive/chymase-postitive mast cells, known to be sensitive to sodium cromolyn, may contribute to the destructive immune process mediated in response to exogenous insulin.	Cromolyn Sodium	86-101	insulin	Homo sapiens	186-193
18787779-8	2008	Sodium cromoglycate inhibited the ET-1-induced neutrophil accumulation in the heart and intestine and did not influence MPO activity in the lung.	Cromolyn Sodium	0-19	endothelin 1	Rattus norvegicus	34-38
18087164-6	2008	Mast cell stabilization with cromolyn or lodoxamide markedly attenuated the release of beta-hexosaminidase, renin and norepinephrine.	Cromolyn Sodium	29-37	O-GlcNAcase	Homo sapiens	87-106
18087164-6	2008	Mast cell stabilization with cromolyn or lodoxamide markedly attenuated the release of beta-hexosaminidase, renin and norepinephrine.	Cromolyn Sodium	29-37	renin	Homo sapiens	108-113
17724738-0	2008	Disodium cromoglycate protects dystrophin-deficient muscle fibers from leakiness.	Cromolyn Sodium	0-21	dystrophin, muscular dystrophy	Mus musculus	31-41
17876882-8	2007	CS could attenuate the up-regulation of the Chiu"s score, the levels of MDA, TNF-alpha, and expression of tryptase and the down-regulation of SOD activity and histamine concentration.	Cromolyn Sodium	0-2	tryptase alpha/beta 1	Rattus norvegicus	106-114
18634614-6	2007	Pharmacological stabilization of mast cells by disodium cromoglycate administration to EGFR(+) mice also diminished loss of axon-Schwann cell interaction.	Cromolyn Sodium	47-68	epidermal growth factor receptor	Mus musculus	87-91
17179482-0	2006	Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models.	Cromolyn Sodium	10-18	predicted gene, 40318	Mus musculus	22-27
17404811-7	2007	Uptake of fluorescein, a MRP1 substrate, was increased (203-290%) in the presence of uricosuric drug probenecid at 100 microM, anti-inflammatory drug indomethacin at 10 microM and diclofenac, flurbiprofen, and ofloxacin at 1 mM, and by ATP depletion, but not influenced by the depletion of GSH, and the presence of antiviral cidofovir and anti-inflammatory drug cromolyn and prednisolone.	Cromolyn Sodium	362-370	ATP-dependent translocase ABCB1	Oryctolagus cuniculus	25-29
17606844-7	2007	Pharmacological MC stabilization with cromoglycate led to significant reduction in tPA-mediated HF at 3 (97%), 6 (76%), and 24 hours (96%) compared with controls (P<0.01, P<0.001, and P<0.01, respectively).	Cromolyn Sodium	38-50	plasminogen activator, tissue type	Rattus norvegicus	83-86
17616733-9	2007	Animals treated with disodium cromoglycate showed a decrease in endothelial cell proliferation and in VEGF mRNA expression compared with controls.	Cromolyn Sodium	21-42	vascular endothelial growth factor A	Rattus norvegicus	102-106
17179482-0	2006	Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models.	Cromolyn Sodium	10-18	advanced glycosylation end product-specific receptor	Mus musculus	46-50
17179482-2	2006	In the current study, we investigated the ability of the antiallergy drug, cromolyn, to block S100P function.	Cromolyn Sodium	75-83	predicted gene, 40318	Mus musculus	94-99
17179482-3	2006	METHODS: Interactions between cromolyn and S100P were investigated using a drug affinity column and by examining cromolyn"s effects on coimmunoprecipitation of S100P and receptor for advanced glycation end-products (RAGE).	Cromolyn Sodium	113-121	predicted gene, 40318	Mus musculus	160-178
17179482-8	2006	RESULTS: S100P was retained on a cromolyn affinity column.	Cromolyn Sodium	33-41	predicted gene, 40318	Mus musculus	9-14
17179482-9	2006	Cromolyn blocked the coimmunoprecipitation of S100P and RAGE.	Cromolyn Sodium	0-8	predicted gene, 40318	Mus musculus	46-51
17179482-9	2006	Cromolyn blocked the coimmunoprecipitation of S100P and RAGE.	Cromolyn Sodium	0-8	advanced glycosylation end product-specific receptor	Mus musculus	56-60
17179482-13	2006	CONCLUSION: Cromolyn binds S100P, prevents activation of RAGE, inhibits tumor growth, and increases the effectiveness of gemcitabine in experimental models.	Cromolyn Sodium	12-20	predicted gene, 40318	Mus musculus	27-32
16707156-0	2006	Binding of anti-inflammatory drug cromolyn sodium to bovine serum albumin.	Cromolyn Sodium	34-49	albumin	Homo sapiens	60-73
16707156-1	2006	Fluorescence spectroscopy in combination with circular dichroism (CD) and UV-vis absorption spectroscopy were employed to investigate the binding of anti-inflammatory drug cromolyn sodium (Intal) to bovine serum albumin (BSA) under the physiological conditions with Intal concentrations of 0-6.4 x 10(-5)mol L(-1).	Cromolyn Sodium	172-187	albumin	Homo sapiens	206-219
17082646-8	2006	To recapitulate the negative mast cell regulation observed in the DR(+/+) rats, we treated DRlyp/lyp rats with the mast cell "stabilizer" cromolyn, which significantly (p < 0.05) delayed T1DM onset.	Cromolyn Sodium	138-146	Insulin dependent diabetes mellitus QTL 2	Rattus norvegicus	93-96
17192560-8	2006	Cromolyn, a mast cell stabilizer, completely blocked Fos expression in the PVN and CeA, and precluded the development of aversion to the dark compartment associated with nebulized OVA.	Cromolyn Sodium	0-8	FBJ osteosarcoma oncogene	Mus musculus	53-56
17192560-8	2006	Cromolyn, a mast cell stabilizer, completely blocked Fos expression in the PVN and CeA, and precluded the development of aversion to the dark compartment associated with nebulized OVA.	Cromolyn Sodium	0-8	carcinoembryonic antigen gene family	Mus musculus	83-86
17179482-13	2006	CONCLUSION: Cromolyn binds S100P, prevents activation of RAGE, inhibits tumor growth, and increases the effectiveness of gemcitabine in experimental models.	Cromolyn Sodium	12-20	advanced glycosylation end product-specific receptor	Mus musculus	57-61
16126393-0	2005	Interaction of cromolyn sodium with human serum albumin: a fluorescence quenching study.	Cromolyn Sodium	15-30	albumin	Homo sapiens	42-55
16767373-9	2006	In both the neuropeptide-depleted and the DSCG-treated groups, eosinophil infiltration and VCAM-1 expression were suppressed in comparison with the nontreated group.	Cromolyn Sodium	42-46	vascular cell adhesion molecule 1	Mus musculus	91-97
16614391-10	2006	Enhanced pulmonary vascular permeability induced by UCN was markedly inhibited by pretreatment with the mast-cell stabilizer cromolyn and histamine-1 (H1) receptor antagonist azelastine respectively, but not by the leukotriene receptor antagonist montelukast.	Cromolyn Sodium	125-133	urocortin	Rattus norvegicus	52-55
16585966-8	2006	Mast cell stabilization with cromolyn or lodoxamide markedly reduced active renin overflow and attenuated both norepinephrine release and arrhythmias.	Cromolyn Sodium	29-37	renin	Cavia porcellus	76-81
16126393-1	2005	The interaction between cromolyn sodium (CS) and human serum albumin (HSA) was investigated using tryptophan fluorescence quenching.	Cromolyn Sodium	24-39	albumin	Homo sapiens	55-74
16126393-1	2005	The interaction between cromolyn sodium (CS) and human serum albumin (HSA) was investigated using tryptophan fluorescence quenching.	Cromolyn Sodium	41-43	albumin	Homo sapiens	55-74
16126393-2	2005	In the discussion of the mechanism, it was proved that the fluorescence quenching of HSA by CS is a result of the formation of a CS-HSA complex.	Cromolyn Sodium	92-94	albumin	Homo sapiens	85-88
16126393-2	2005	In the discussion of the mechanism, it was proved that the fluorescence quenching of HSA by CS is a result of the formation of a CS-HSA complex.	Cromolyn Sodium	92-94	albumin	Homo sapiens	132-135
16126393-2	2005	In the discussion of the mechanism, it was proved that the fluorescence quenching of HSA by CS is a result of the formation of a CS-HSA complex.	Cromolyn Sodium	129-131	albumin	Homo sapiens	85-88
16126393-2	2005	In the discussion of the mechanism, it was proved that the fluorescence quenching of HSA by CS is a result of the formation of a CS-HSA complex.	Cromolyn Sodium	129-131	albumin	Homo sapiens	132-135
16126393-3	2005	Quenching constants were determined using the Sterns-Volmer equation to provide a measure of the binding affinity between CS and HSA.	Cromolyn Sodium	122-124	albumin	Homo sapiens	129-132
16126393-6	2005	Furthermore, synchronous fluorescence spectroscopy data and UV-vis absorbance spectra have suggested that the association between CS and HSA changed the molecular conformation of HSA and the electrostatic interactions play a major role in CS-HSA association.	Cromolyn Sodium	130-132	albumin	Homo sapiens	137-140
16126393-6	2005	Furthermore, synchronous fluorescence spectroscopy data and UV-vis absorbance spectra have suggested that the association between CS and HSA changed the molecular conformation of HSA and the electrostatic interactions play a major role in CS-HSA association.	Cromolyn Sodium	130-132	albumin	Homo sapiens	179-182
16126393-6	2005	Furthermore, synchronous fluorescence spectroscopy data and UV-vis absorbance spectra have suggested that the association between CS and HSA changed the molecular conformation of HSA and the electrostatic interactions play a major role in CS-HSA association.	Cromolyn Sodium	130-132	albumin	Homo sapiens	179-182
16126393-6	2005	Furthermore, synchronous fluorescence spectroscopy data and UV-vis absorbance spectra have suggested that the association between CS and HSA changed the molecular conformation of HSA and the electrostatic interactions play a major role in CS-HSA association.	Cromolyn Sodium	239-241	albumin	Homo sapiens	137-140
16126393-6	2005	Furthermore, synchronous fluorescence spectroscopy data and UV-vis absorbance spectra have suggested that the association between CS and HSA changed the molecular conformation of HSA and the electrostatic interactions play a major role in CS-HSA association.	Cromolyn Sodium	239-241	albumin	Homo sapiens	179-182
16126393-6	2005	Furthermore, synchronous fluorescence spectroscopy data and UV-vis absorbance spectra have suggested that the association between CS and HSA changed the molecular conformation of HSA and the electrostatic interactions play a major role in CS-HSA association.	Cromolyn Sodium	239-241	albumin	Homo sapiens	179-182
16211461-9	2005	Cromolyn prevented a decreased expression of PECAM-1 on circulatory neutrophils and monocytes/macrophages and against an increased expression of ICAM-1 and PECAM-1 on pulmonary neutrophils and monocytes/macrophages 6 hours after AP induction (about 40% vs. 10%, p < 0.01).	Cromolyn Sodium	0-8	platelet and endothelial cell adhesion molecule 1	Rattus norvegicus	45-52
16205096-1	2005	BACKGROUND: Disodium cromoglycate (DSCG) is known to inhibit both immediate and late asthmatic responses (IAR and LAR).	Cromolyn Sodium	12-33	low antibody response	Mus musculus	114-117
16205096-1	2005	BACKGROUND: Disodium cromoglycate (DSCG) is known to inhibit both immediate and late asthmatic responses (IAR and LAR).	Cromolyn Sodium	35-39	low antibody response	Mus musculus	114-117
16211461-9	2005	Cromolyn prevented a decreased expression of PECAM-1 on circulatory neutrophils and monocytes/macrophages and against an increased expression of ICAM-1 and PECAM-1 on pulmonary neutrophils and monocytes/macrophages 6 hours after AP induction (about 40% vs. 10%, p < 0.01).	Cromolyn Sodium	0-8	intercellular adhesion molecule 1	Rattus norvegicus	145-151
16211461-9	2005	Cromolyn prevented a decreased expression of PECAM-1 on circulatory neutrophils and monocytes/macrophages and against an increased expression of ICAM-1 and PECAM-1 on pulmonary neutrophils and monocytes/macrophages 6 hours after AP induction (about 40% vs. 10%, p < 0.01).	Cromolyn Sodium	0-8	platelet and endothelial cell adhesion molecule 1	Rattus norvegicus	156-163
14500682-3	2003	Administration of sodium cromoglycate (40 mg/kg, i.p., 1 h before Der f instillation), a mast cell stabilizer, not only suppressed acute mouse mast cell protease 1 production but also attenuated the allergic airway inflammation provoked by repetitive Der f challenge in mice (five times at 1-wk interval).	Cromolyn Sodium	18-37	mast cell protease 1	Mus musculus	143-163
15002759-9	2004	CONCLUSIONS: Our results indicate that DSCG suppresses the DMSO-induced LTC4 synthase-activity by inhibiting mRNA expression of LTC4 synthase, which might be a novel anti-allergic action of DSCG.	Cromolyn Sodium	39-43	leukotriene C4 synthase	Homo sapiens	72-85
15002759-9	2004	CONCLUSIONS: Our results indicate that DSCG suppresses the DMSO-induced LTC4 synthase-activity by inhibiting mRNA expression of LTC4 synthase, which might be a novel anti-allergic action of DSCG.	Cromolyn Sodium	39-43	leukotriene C4 synthase	Homo sapiens	128-141
14602784-7	2003	CRH-induced dilation of the skin microvasculature was significantly reduced in the presence of the mast cell degranulation inhibitor, sodium cromoglycate, the histamine H(1)-antagonist, promethazine, or the H(2)-antagonist, ranitidine.	Cromolyn Sodium	134-153	corticotropin releasing hormone	Homo sapiens	0-3
14659806-8	2003	TNF-alpha release was inhibited in hearts treated with degranulation inhibitors ketotifen or cromoglycate, suggesting mast cells as major source for myocardial TNF-alpha.	Cromolyn Sodium	93-105	tumor necrosis factor	Homo sapiens	0-9
14659806-8	2003	TNF-alpha release was inhibited in hearts treated with degranulation inhibitors ketotifen or cromoglycate, suggesting mast cells as major source for myocardial TNF-alpha.	Cromolyn Sodium	93-105	tumor necrosis factor	Homo sapiens	160-169
14500682-5	2003	Cycloheximide as well as sodium cromoglycate blocked the Der f-induced IL-4 production, indicating a de novo protein synthesis process.	Cromolyn Sodium	25-44	interleukin 4	Mus musculus	71-75
14508201-7	2003	In the presence of an inhibitor of mast cell degranulation, disodium cromoglycate, the induced expression of NF-kappaB and IL-6 was inhibited.	Cromolyn Sodium	60-81	interleukin 6	Rattus norvegicus	123-127
14577597-3	2003	Therefore we tested the effect of cromoglycate sodium salt (cromolyn), an inhibitor of mast cell degranulation with anti-inflammatory and membrane-stabilizing activity, on the increased expression of IL-6 mRNA and of mRNAs of proteins involved in the remodelling of the extracellular matrix (ECM) which is induced by NE (0.1 mg/kg x h).	Cromolyn Sodium	60-68	interleukin 6	Rattus norvegicus	200-204
14577597-6	2003	Cromolyn induced a slight depression of the NE-induced elevation of the matrix metalloproteinase (MMP)-2.	Cromolyn Sodium	0-8	matrix metallopeptidase 2	Rattus norvegicus	72-104
12803546-0	2003	Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox.	Cromolyn Sodium	52-73	heat shock protein 90 alpha family class A member 1	Homo sapiens	0-5
12803546-3	2003	In an effort to discover Hsp90 antagonists, we screened many drugs and found that the anti-allergic drugs DSCG (disodium cromoglycate) and amlexanox target Hsp90.	Cromolyn Sodium	106-110	heat shock protein 90 alpha family class A member 1	Homo sapiens	25-30
12803546-3	2003	In an effort to discover Hsp90 antagonists, we screened many drugs and found that the anti-allergic drugs DSCG (disodium cromoglycate) and amlexanox target Hsp90.	Cromolyn Sodium	106-110	heat shock protein 90 alpha family class A member 1	Homo sapiens	156-161
12803546-3	2003	In an effort to discover Hsp90 antagonists, we screened many drugs and found that the anti-allergic drugs DSCG (disodium cromoglycate) and amlexanox target Hsp90.	Cromolyn Sodium	112-133	heat shock protein 90 alpha family class A member 1	Homo sapiens	25-30
12803546-3	2003	In an effort to discover Hsp90 antagonists, we screened many drugs and found that the anti-allergic drugs DSCG (disodium cromoglycate) and amlexanox target Hsp90.	Cromolyn Sodium	112-133	heat shock protein 90 alpha family class A member 1	Homo sapiens	156-161
12803546-10	2003	DSCG and amlexanox may serve as useful tools for evaluating the physiological significance of Hsp90.	Cromolyn Sodium	0-4	heat shock protein 90 alpha family class A member 1	Homo sapiens	94-99
11417850-3	2001	DSCG strongly inhibited IL-4-dependent IgE production by lipopolysaccharide-stimulated murine whole spleen cells.	Cromolyn Sodium	0-4	interleukin 4	Mus musculus	24-28
12829195-10	2003	Stress-induced IL-6 release was absent in W/W(v) mast cell-deficient mice and it was partially inhibited by cromolyn in C57BL and ApoE mice.	Cromolyn Sodium	108-116	interleukin 6	Mus musculus	15-19
12829195-10	2003	Stress-induced IL-6 release was absent in W/W(v) mast cell-deficient mice and it was partially inhibited by cromolyn in C57BL and ApoE mice.	Cromolyn Sodium	108-116	apolipoprotein E	Mus musculus	130-134
12462286-15	2002	CONCLUSIONS: Six weeks" instillation of olopatadine 0.19% ophthalmic solution BID had a significantly greater effect on the ocular signs and symptoms of allergic conjunctivitis compared with 6 weeks" instillation of cromolyn 2% ophthalmic solution QID.	Cromolyn Sodium	216-224	BH3 interacting domain death agonist	Homo sapiens	78-81
11944917-0	2002	Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein.	Cromolyn Sodium	86-94	S100 calcium binding protein B	Homo sapiens	15-19
11944917-0	2002	Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein.	Cromolyn Sodium	86-94	S100 calcium binding protein A1	Homo sapiens	145-151
11944917-3	2002	Recently, we reported that two antiallergic drugs, Amlexanox and Cromolyn, bind to S100A12 and S100A13 of the S100 protein family.	Cromolyn Sodium	65-73	S100 calcium binding protein A12	Homo sapiens	83-90
11944917-3	2002	Recently, we reported that two antiallergic drugs, Amlexanox and Cromolyn, bind to S100A12 and S100A13 of the S100 protein family.	Cromolyn Sodium	65-73	S100 calcium binding protein A13	Homo sapiens	95-102
11944917-3	2002	Recently, we reported that two antiallergic drugs, Amlexanox and Cromolyn, bind to S100A12 and S100A13 of the S100 protein family.	Cromolyn Sodium	65-73	S100 calcium binding protein B	Homo sapiens	83-87
11831846-6	2002	mNDPK exhibited saturation kinetics with respect to its nucleoside diphosphate acceptors and nucleoside triphosphate donors and sensitivity to known inhibitors of NDPK (e.g., uridine diphosphate and cromoglycate).	Cromolyn Sodium	199-211	cytidine/uridine monophosphate kinase 2	Homo sapiens	1-5
12595955-11	2003	Hypersecretory responses to both gastrin and histamine in iodoacetamide-treated mice were blocked by the mast cell stabilizer sodium cromoglycate, and enhanced by indomethacin, without affecting the secretory response in normal mice.	Cromolyn Sodium	126-145	gastrin	Mus musculus	33-40
12090980-2	2002	Sodium cromoglicate inhibits the ICAM-1 molecule, which is the receptor for human rhinoviruses.	Cromolyn Sodium	0-19	intercellular adhesion molecule 1	Homo sapiens	33-39
11527248-9	2001	After 1 week"s treatment with cromolyn sodium, patients" symptoms, blood and sputum eosinophils counts, and sputum ECP levels were significantly decreased compared with both placebo and baseline.	Cromolyn Sodium	30-45	ribonuclease A family member 3	Homo sapiens	115-118
11527248-11	2001	This is the first report that cromolyn sodium reduces blood and sputum eosinophils counts and sputum ECP levels in AIA.	Cromolyn Sodium	30-45	ribonuclease A family member 3	Homo sapiens	101-104
11477207-9	2001	Finally, cromoglycate or antihistamine drugs significantly reduced ibotenate-induced brain lesions in IL-9-treated Swiss pups.	Cromolyn Sodium	9-21	interleukin 9	Mus musculus	102-106
10772941-3	2000	Binding of 36-kDa MAGP to tranilast seemed to be specific since 36-kDa MAGP could be eluted from the drug affinity column by tranilast itself and also binding of 36-kDa MAGP to other anti-allergy drugs (amlexanox and cromolyn) is significantly weaker than that to tranilast.	Cromolyn Sodium	217-225	microfibril associated protein 2	Homo sapiens	18-22
10945828-5	2000	Moesin phosphorylated in mast cells treated with cromolyn shifted from the soluble to the precipitable fraction and associated with Sepharose-linked beta-actin.	Cromolyn Sodium	49-57	moesin	Rattus norvegicus	0-6
10945828-5	2000	Moesin phosphorylated in mast cells treated with cromolyn shifted from the soluble to the precipitable fraction and associated with Sepharose-linked beta-actin.	Cromolyn Sodium	49-57	actin, beta	Rattus norvegicus	149-159
10945828-11	2000	Cromolyn appeared to induce clustering of moesin around secretory granules.	Cromolyn Sodium	0-8	moesin	Rattus norvegicus	42-48
10871319-7	2000	Two mast-cell stabilizers, cromolyn and lodoxamide, markedly reduced NE release, implicating cardiac mast cells as a major source of chymase.	Cromolyn Sodium	27-35	chymase 1	Homo sapiens	133-140
10772941-3	2000	Binding of 36-kDa MAGP to tranilast seemed to be specific since 36-kDa MAGP could be eluted from the drug affinity column by tranilast itself and also binding of 36-kDa MAGP to other anti-allergy drugs (amlexanox and cromolyn) is significantly weaker than that to tranilast.	Cromolyn Sodium	217-225	microfibril associated protein 2	Homo sapiens	71-75
10772941-3	2000	Binding of 36-kDa MAGP to tranilast seemed to be specific since 36-kDa MAGP could be eluted from the drug affinity column by tranilast itself and also binding of 36-kDa MAGP to other anti-allergy drugs (amlexanox and cromolyn) is significantly weaker than that to tranilast.	Cromolyn Sodium	217-225	microfibril associated protein 2	Homo sapiens	71-75
10674568-3	2000	OBJECTIVE: We investigated whether DSCG inhibited the expression of IL-5 and TNF-alpha mRNA and proteins from isolated human lungs, and compared these findings with those of Dex.	Cromolyn Sodium	35-39	interleukin 5	Homo sapiens	68-72
10674568-3	2000	OBJECTIVE: We investigated whether DSCG inhibited the expression of IL-5 and TNF-alpha mRNA and proteins from isolated human lungs, and compared these findings with those of Dex.	Cromolyn Sodium	35-39	tumor necrosis factor	Homo sapiens	77-86
10654519-7	2000	In contrast with ICAM-1, NOS-2 expression was increased by ketotifen or cromolyn treatment (464+/-82 in group B and 507+/-93 in group C, compared with 377+/-44 for group A, p = 0.007).	Cromolyn Sodium	72-80	nitric oxide synthase 2	Rattus norvegicus	25-30
10430611-6	1999	The EPR was blocked by cromoglycate and albuterol, whereas the LPR was abolished by cromoglycate and hydrocortisone.	Cromolyn Sodium	84-96	Fas (TNF receptor superfamily member 6)	Mus musculus	63-66
10674568-15	2000	CONCLUSION: Our results showed that DSCG significantly inhibited IL-5 and TNF-alpha production by human lung specimens, suggesting that it acts as an anti-inflammatory agent.	Cromolyn Sodium	36-40	interleukin 5	Homo sapiens	65-69
10674568-15	2000	CONCLUSION: Our results showed that DSCG significantly inhibited IL-5 and TNF-alpha production by human lung specimens, suggesting that it acts as an anti-inflammatory agent.	Cromolyn Sodium	36-40	tumor necrosis factor	Homo sapiens	74-83
10027877-5	1999	Ucn-induced skin vasodilation was inhibited by pretreatment with the mast cell stabilizer disodium cromoglycate (cromolyn) and was absent in the mast cell-deficient W/Wv mice.	Cromolyn Sodium	90-111	urocortin	Mus musculus	0-3
10051426-0	1999	Three distinct anti-allergic drugs, amlexanox, cromolyn and tranilast, bind to S100A12 and S100A13 of the S100 protein family.	Cromolyn Sodium	47-55	S100 calcium binding protein A12	Bos taurus	79-86
10051426-0	1999	Three distinct anti-allergic drugs, amlexanox, cromolyn and tranilast, bind to S100A12 and S100A13 of the S100 protein family.	Cromolyn Sodium	47-55	S100 calcium binding protein A13	Bos taurus	91-98
10027877-5	1999	Ucn-induced skin vasodilation was inhibited by pretreatment with the mast cell stabilizer disodium cromoglycate (cromolyn) and was absent in the mast cell-deficient W/Wv mice.	Cromolyn Sodium	113-121	urocortin	Mus musculus	0-3
9792213-7	1998	In fact, treatments of animals with (1) histamine H1 or serotonin antagonists or with (2) the mast cell stabilizer cromolyn or with (3) prior depletion of intact mast cells are maneuvers that successfully reduce eosinophil, neutrophil and monocyte extravasation in response to eotaxin, interleukin-8 or monocyte chemoattractant protein-1, respectively.	Cromolyn Sodium	115-123	C-C motif chemokine ligand 11	Homo sapiens	277-284
10208836-1	1999	The beta2-adrenoceptor agonist reproterol and disodium cromoglycate (DSCG) are used in fixed combination for the treatment of asthma, because they act on bronchial smooth muscle and inflammatory cells, respectively.	Cromolyn Sodium	69-73	adrenoceptor beta 2	Rattus norvegicus	4-22
9792213-7	1998	In fact, treatments of animals with (1) histamine H1 or serotonin antagonists or with (2) the mast cell stabilizer cromolyn or with (3) prior depletion of intact mast cells are maneuvers that successfully reduce eosinophil, neutrophil and monocyte extravasation in response to eotaxin, interleukin-8 or monocyte chemoattractant protein-1, respectively.	Cromolyn Sodium	115-123	C-X-C motif chemokine ligand 8	Homo sapiens	286-299
9792213-7	1998	In fact, treatments of animals with (1) histamine H1 or serotonin antagonists or with (2) the mast cell stabilizer cromolyn or with (3) prior depletion of intact mast cells are maneuvers that successfully reduce eosinophil, neutrophil and monocyte extravasation in response to eotaxin, interleukin-8 or monocyte chemoattractant protein-1, respectively.	Cromolyn Sodium	115-123	C-C motif chemokine ligand 2	Homo sapiens	303-337
9877232-4	1998	NDP kinase exhibited saturation kinetics towards di- and tri-phosphate substrates, and was inhibited by known inhibitors of NDP kinase, uridine diphosphate (UDP) or cromoglycate (CRG).	Cromolyn Sodium	165-177	cytidine/uridine monophosphate kinase 1	Rattus norvegicus	0-10
9859903-0	1998	Effects of inhaled corticosteroids and inhaled cromolyn sodium on urinary growth hormone excretion in asthmatic children.	Cromolyn Sodium	47-62	growth hormone 1	Homo sapiens	74-88
9753268-4	1998	Pretreatment with sodium cromoglycate prevented the clinical signs of anaphylaxis and significantly diminished the infiltration of neutrophils in +/+ or Kit(W)/Kit(W-v) mice.	Cromolyn Sodium	18-37	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	153-156
9753268-4	1998	Pretreatment with sodium cromoglycate prevented the clinical signs of anaphylaxis and significantly diminished the infiltration of neutrophils in +/+ or Kit(W)/Kit(W-v) mice.	Cromolyn Sodium	18-37	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	160-163
16495900-2	1998	BACKGROUND AND AIMS: This study highlights the possibility of treating recidivating ulcerative rectocolitis with oral disodium cromoglycate based on the assay of plasma IgE.	Cromolyn Sodium	118-139	immunoglobulin heavy constant epsilon	Homo sapiens	169-172
9877232-4	1998	NDP kinase exhibited saturation kinetics towards di- and tri-phosphate substrates, and was inhibited by known inhibitors of NDP kinase, uridine diphosphate (UDP) or cromoglycate (CRG).	Cromolyn Sodium	179-182	cytidine/uridine monophosphate kinase 1	Rattus norvegicus	0-10
9877232-4	1998	NDP kinase exhibited saturation kinetics towards di- and tri-phosphate substrates, and was inhibited by known inhibitors of NDP kinase, uridine diphosphate (UDP) or cromoglycate (CRG).	Cromolyn Sodium	179-182	cytidine/uridine monophosphate kinase 1	Rattus norvegicus	124-134
9675912-0	1998	Binding of disodium cromoglycate to human serum albumin.	Cromolyn Sodium	11-32	albumin	Homo sapiens	42-55
9675912-2	1998	The antiallergic drug disodium cromoglycate binds weakly to serum albumin.	Cromolyn Sodium	22-43	albumin	Homo sapiens	60-73
9388479-0	1997	Two distinct anti-allergic drugs, amlexanox and cromolyn, bind to the same kinds of calcium binding proteins, except calmodulin, in bovine lung extract.	Cromolyn Sodium	48-56	calmodulin	Bos taurus	117-127
10070568-13	1998	Comparing before- and after-treatment values, only the DSCG group exhibited a significant decrease in the number of CD8+ T cells (P < 0.01).	Cromolyn Sodium	55-59	CD8a molecule	Homo sapiens	116-119
9421440-11	1998	The effect of CRH on Evans blue extravasation and mast cell degranulation was inhibited by the mast cell stabilizer disodium cromoglycate (cromolyn), but not by the antisecretory molecule somatostatin.	Cromolyn Sodium	116-137	corticotropin releasing hormone	Rattus norvegicus	14-17
9421440-11	1998	The effect of CRH on Evans blue extravasation and mast cell degranulation was inhibited by the mast cell stabilizer disodium cromoglycate (cromolyn), but not by the antisecretory molecule somatostatin.	Cromolyn Sodium	139-147	corticotropin releasing hormone	Rattus norvegicus	14-17
10453751-6	1998	The most significant finding was a significant decrease of ICAM-1 expression on monocytes and CD49d on monocytes and lymphocytes as well as an increase of L-selectin expression on monocytes after treatment with DSCG, without any associated effect on CD11a and CD18.	Cromolyn Sodium	211-215	selectin L	Homo sapiens	155-165
10453751-6	1998	The most significant finding was a significant decrease of ICAM-1 expression on monocytes and CD49d on monocytes and lymphocytes as well as an increase of L-selectin expression on monocytes after treatment with DSCG, without any associated effect on CD11a and CD18.	Cromolyn Sodium	211-215	integrin subunit beta 2	Homo sapiens	260-264
10453751-7	1998	The levels of soluble ICAM-1 and VCAM-1 were not changed, only the levels of soluble CD23 that plays a regulatory role in ongoing IgE production, were decreased in asthmatic patients after the treatment with DSCG.	Cromolyn Sodium	208-212	intercellular adhesion molecule 1	Homo sapiens	22-28
10453751-7	1998	The levels of soluble ICAM-1 and VCAM-1 were not changed, only the levels of soluble CD23 that plays a regulatory role in ongoing IgE production, were decreased in asthmatic patients after the treatment with DSCG.	Cromolyn Sodium	208-212	vascular cell adhesion molecule 1	Homo sapiens	33-39
10453751-7	1998	The levels of soluble ICAM-1 and VCAM-1 were not changed, only the levels of soluble CD23 that plays a regulatory role in ongoing IgE production, were decreased in asthmatic patients after the treatment with DSCG.	Cromolyn Sodium	208-212	Fc epsilon receptor II	Homo sapiens	85-89
9106069-2	1997	Sodium cromoglycate was extracted from urine on a 100-mg phenyl cartridge (Isolute, Jones Chromatography) and then quantified on a 25-cm C8 Spherisorb 5 microns stationary phase with a mobile phase of methanol-0.045 M phosphate buffer-0.05 M dodecyl triethyl ammonium phosphate (550:447.6:2.4, v/v) pH 2.3, at 0.85 ml min-1 using nedocromil sodium as an internal standard and UV detection at 238 nm.	Cromolyn Sodium	0-19	CD59 molecule (CD59 blood group)	Homo sapiens	318-323
9372670-8	1997	There was a trend towards lower IL-1 beta levels in DSCG-treated infants on Day 7, but IL-1ra levels were unaffected by DSCG therapy.	Cromolyn Sodium	52-56	interleukin 1 beta	Homo sapiens	32-41
9261851-7	1997	Children with high concentrations of respiratory tract ECP seemed to benefit from anti-inflammatory therapy with nebulized cromolyn sodium or budesonide; both drugs significantly decreased the number of subsequent physician-diagnosed bronchial obstruction (P = 0.0006), and they tended to decrease the number of hospital admissions for wheezing (P = 0.08).	Cromolyn Sodium	123-138	ribonuclease A family member 3	Homo sapiens	55-58
9184721-0	1997	Cromolyn sodium for ACE inhibitor-induced cough.	Cromolyn Sodium	0-15	angiotensin I converting enzyme	Homo sapiens	20-23
9184721-7	1997	Cromolyn sodium has been effective for the treatment of ACE inhibitor-induced cough in many case reports and has had mild success in one small clinical trial.	Cromolyn Sodium	0-15	angiotensin I converting enzyme	Homo sapiens	56-59
9184721-11	1997	At this time, the use of cromolyn sodium is a viable option, but more controlled studies are needed to fully elucidate its role in the treatment of ACE inhibitor-induced cough.	Cromolyn Sodium	25-40	angiotensin I converting enzyme	Homo sapiens	148-151
9088653-0	1997	Allergic rhinitis in children: effects of flunisolide and disodium cromoglycate on nasal eosinophil cationic protein.	Cromolyn Sodium	58-79	ribonuclease A family member 3	Homo sapiens	89-116
9135403-0	1997	Effect of lodoxamide and disodium cromoglycate on tear eosinophil cationic protein in vernal keratoconjunctivitis.	Cromolyn Sodium	25-46	ribonuclease A family member 3	Homo sapiens	55-82
9552432-2	1997	Disodium cromoglycate was treated with a homologous series of saturated fatty acids, between C8 and C18, in a range of concentrations.	Cromolyn Sodium	0-21	Bardet-Biedl syndrome 9	Homo sapiens	100-103
8688342-2	1996	A recent report demonstrated that inhaled sodium cromoglycate is an effective treatment for ACE inhibitors" cough; this effect might be due to the suppression of afferent unmyelinated C-fibres.	Cromolyn Sodium	42-61	angiotensin I converting enzyme	Homo sapiens	92-95
8856193-8	1996	The main component of this drug (disodium chromoglycate) inhibited the activity of leukocyte elastase in experiments in vitro.	Cromolyn Sodium	33-55	elastase, neutrophil expressed	Homo sapiens	83-101
8927789-8	1996	ACE-induced cough usually disappears within 1 to 4 days after withdrawal of the treatment, confirming the diagnosis; ACE-induced cough may be prevented by sodium cromoglycate.	Cromolyn Sodium	155-174	angiotensin I converting enzyme	Homo sapiens	0-3
8927789-8	1996	ACE-induced cough usually disappears within 1 to 4 days after withdrawal of the treatment, confirming the diagnosis; ACE-induced cough may be prevented by sodium cromoglycate.	Cromolyn Sodium	155-174	angiotensin I converting enzyme	Homo sapiens	117-120
7554404-0	1995	Inhibition of tumour necrosis factor-alpha (TNF-alpha) release from mast cells by the anti-inflammatory drugs, sodium cromoglycate and nedocromil sodium.	Cromolyn Sodium	111-130	tumor necrosis factor	Rattus norvegicus	44-53
8560161-11	1995	The data suggest that changes of IgE and inflammatory mediators may be affected by the use of sodium cromoglycate in both groups, but some parameters change early in different directions in IT- and placebo-treated groups.	Cromolyn Sodium	94-113	immunoglobulin heavy constant epsilon	Homo sapiens	33-36
8123570-6	1994	The proliferation-modulatory effects of NGF were associated with the induction of significant mast cell degranulation, and were inhibited by cromoglycate co-administration.	Cromolyn Sodium	141-153	nerve growth factor	Mus musculus	40-43
7799699-0	1995	Inhaled sodium cromoglycate in angiotensin-converting enzyme inhibitor cough.	Cromolyn Sodium	8-27	angiotensin I converting enzyme	Homo sapiens	31-60
7799699-2	1995	We examined the effects of inhaled sodium cromoglycate in 10 patients with ACE-inhibitor cough in a double-blind crossover study.	Cromolyn Sodium	35-54	angiotensin I converting enzyme	Homo sapiens	75-78
7799699-11	1995	Inhaled sodium cromoglycate is an effective treatment for ACE-inhibitor cough.	Cromolyn Sodium	8-27	angiotensin I converting enzyme	Homo sapiens	58-61
7582506-0	1995	Inhibition by cromoglycate and some flavonoids of nucleoside diphosphate kinase and of exocytosis from permeabilized mast cells.	Cromolyn Sodium	14-26	cytidine/uridine monophosphate kinase 2	Homo sapiens	50-79
7582506-2	1995	The anti-allergic compound, cromoglycate, is reported to possess affinity for, and to suppress the autophosphorylation of a 72kDa protein having the sequence of nucleoside diphosphate kinase (NDPK).	Cromolyn Sodium	28-40	cytidine/uridine monophosphate kinase 2	Homo sapiens	161-190
7582506-2	1995	The anti-allergic compound, cromoglycate, is reported to possess affinity for, and to suppress the autophosphorylation of a 72kDa protein having the sequence of nucleoside diphosphate kinase (NDPK).	Cromolyn Sodium	28-40	cytidine/uridine monophosphate kinase 2	Homo sapiens	192-196
7582506-4	1995	We have tested the ability of cromoglycate, and a panel of ten structurally related flavonoids of plant origin, to inhibit the NDPK reaction and the exocytotic process of permeabilized mast cells.	Cromolyn Sodium	30-42	cytidine/uridine monophosphate kinase 2	Homo sapiens	127-131
7582506-8	1995	We found that cromoglycate does not discriminate between Ca2+ and GTP-gamma-S-induced exocytosis and is a poor inhibitor of NDPK activity.	Cromolyn Sodium	14-26	cytidine/uridine monophosphate kinase 2	Homo sapiens	124-128
7668997-6	1995	The number of eosinophils, mast cells, T lymphocytes and macrophages were significantly decreased, and the expression of ICAM-1, VCAM-1 and ELAM-1 were significantly inhibited by the administration of DSCG.	Cromolyn Sodium	201-205	intercellular adhesion molecule 1	Homo sapiens	121-127
7668997-6	1995	The number of eosinophils, mast cells, T lymphocytes and macrophages were significantly decreased, and the expression of ICAM-1, VCAM-1 and ELAM-1 were significantly inhibited by the administration of DSCG.	Cromolyn Sodium	201-205	vascular cell adhesion molecule 1	Homo sapiens	129-135
7668997-6	1995	The number of eosinophils, mast cells, T lymphocytes and macrophages were significantly decreased, and the expression of ICAM-1, VCAM-1 and ELAM-1 were significantly inhibited by the administration of DSCG.	Cromolyn Sodium	201-205	selectin E	Homo sapiens	140-146
7590895-5	1995	Expression of the TNF-inducible CD62E (E-selectin/ELAM-1) and CD54 adhesion molecules on cutaneous endothelium occurred 2 h following mast cell degranulation, and this event was sensitive to blockade of mast cells with disodium cromoglycate.	Cromolyn Sodium	219-240	tumor necrosis factor	Homo sapiens	18-21
7590895-5	1995	Expression of the TNF-inducible CD62E (E-selectin/ELAM-1) and CD54 adhesion molecules on cutaneous endothelium occurred 2 h following mast cell degranulation, and this event was sensitive to blockade of mast cells with disodium cromoglycate.	Cromolyn Sodium	219-240	selectin E	Homo sapiens	32-37
7590895-5	1995	Expression of the TNF-inducible CD62E (E-selectin/ELAM-1) and CD54 adhesion molecules on cutaneous endothelium occurred 2 h following mast cell degranulation, and this event was sensitive to blockade of mast cells with disodium cromoglycate.	Cromolyn Sodium	219-240	selectin E	Homo sapiens	39-49
7590895-5	1995	Expression of the TNF-inducible CD62E (E-selectin/ELAM-1) and CD54 adhesion molecules on cutaneous endothelium occurred 2 h following mast cell degranulation, and this event was sensitive to blockade of mast cells with disodium cromoglycate.	Cromolyn Sodium	219-240	selectin E	Homo sapiens	50-56
7590895-5	1995	Expression of the TNF-inducible CD62E (E-selectin/ELAM-1) and CD54 adhesion molecules on cutaneous endothelium occurred 2 h following mast cell degranulation, and this event was sensitive to blockade of mast cells with disodium cromoglycate.	Cromolyn Sodium	219-240	intercellular adhesion molecule 1	Homo sapiens	62-66
7473348-5	1995	Compared to levels in controls, post-irradiation hippocampal blood flow (rCBF) levels were higher in monkeys receiving DSCG, AH or METH.	Cromolyn Sodium	119-123	CCAAT/enhancer binding protein zeta	Rattus norvegicus	73-77
7897224-3	1995	Preincubation of neutrophils with the asthma drug cromolyn sodium selectively inhibited FMLP (10(-7) M) and PMA (0.1 microgram/ml) elicited O2- generation but not degranulation.	Cromolyn Sodium	50-65	formyl peptide receptor 1	Homo sapiens	88-92
7897224-6	1995	Ca2+ mobilization triggered by FMLP was significantly decreased by 21.2% in cromolyn-treated cells.	Cromolyn Sodium	76-84	formyl peptide receptor 1	Homo sapiens	31-35
7545881-0	1995	The effect of disodium cromoglycate (DSCG) on in vitro proliferation of CD4+, CD8+, and CD19+ cell populations derived from allergic and healthy donors.	Cromolyn Sodium	14-35	CD4 molecule	Homo sapiens	72-75
7545881-0	1995	The effect of disodium cromoglycate (DSCG) on in vitro proliferation of CD4+, CD8+, and CD19+ cell populations derived from allergic and healthy donors.	Cromolyn Sodium	14-35	CD19 molecule	Homo sapiens	88-92
7545881-0	1995	The effect of disodium cromoglycate (DSCG) on in vitro proliferation of CD4+, CD8+, and CD19+ cell populations derived from allergic and healthy donors.	Cromolyn Sodium	37-41	CD4 molecule	Homo sapiens	72-75
7545881-0	1995	The effect of disodium cromoglycate (DSCG) on in vitro proliferation of CD4+, CD8+, and CD19+ cell populations derived from allergic and healthy donors.	Cromolyn Sodium	37-41	CD19 molecule	Homo sapiens	88-92
7545881-1	1995	The effect of disodium cromoglycate (DSCG) on in vitro proliferation of CD4+ and CD8+ T cells and CD19+ B cells, positively selected by immunomagnetic separation, was investigated.	Cromolyn Sodium	14-35	CD4 molecule	Homo sapiens	72-75
7545881-1	1995	The effect of disodium cromoglycate (DSCG) on in vitro proliferation of CD4+ and CD8+ T cells and CD19+ B cells, positively selected by immunomagnetic separation, was investigated.	Cromolyn Sodium	14-35	CD8a molecule	Homo sapiens	81-84
7545881-1	1995	The effect of disodium cromoglycate (DSCG) on in vitro proliferation of CD4+ and CD8+ T cells and CD19+ B cells, positively selected by immunomagnetic separation, was investigated.	Cromolyn Sodium	37-41	CD4 molecule	Homo sapiens	72-75
7545881-1	1995	The effect of disodium cromoglycate (DSCG) on in vitro proliferation of CD4+ and CD8+ T cells and CD19+ B cells, positively selected by immunomagnetic separation, was investigated.	Cromolyn Sodium	37-41	CD8a molecule	Homo sapiens	81-84
7545881-4	1995	Proliferative responses of T- and B-cell subsets stimulated with mitogens together with recombinant interleukin-2 (rIL-2) or accessory cells (AC) could be inhibited by DSCG.	Cromolyn Sodium	168-172	interleukin 2	Homo sapiens	100-113
7545881-4	1995	Proliferative responses of T- and B-cell subsets stimulated with mitogens together with recombinant interleukin-2 (rIL-2) or accessory cells (AC) could be inhibited by DSCG.	Cromolyn Sodium	168-172	interleukin 2	Rattus norvegicus	115-120
7545881-11	1995	Our results show that DSCG delivers an inhibitory signal or signals to PBMC subpopulations expressing Fc epsilon RII/sCD23, either upregulated by phytohemagglutinin in normal and atopic cells, or by allergens or sCD23 in atopic cells.	Cromolyn Sodium	22-26	Fc epsilon receptor II	Homo sapiens	102-116
8046339-5	1994	DSCG did not interfere with CD40 ligand expression by T cells but clearly targeted the B cells because it inhibited IgE synthesis induced by anti-CD40 and IL-4 in populations of highly purified B cells.	Cromolyn Sodium	0-4	CD40 molecule	Homo sapiens	146-150
8046339-5	1994	DSCG did not interfere with CD40 ligand expression by T cells but clearly targeted the B cells because it inhibited IgE synthesis induced by anti-CD40 and IL-4 in populations of highly purified B cells.	Cromolyn Sodium	0-4	interleukin 4	Homo sapiens	155-159
7683300-6	1993	Histamine release in the presence of rIL-3 was inhibited by TYB-2285 and disodium cromoglycate (DSCG) in a dose-dependent manner (1-100 microM).	Cromolyn Sodium	73-94	interleukin 3	Rattus norvegicus	37-42
8345216-6	1993	Furthermore, preincubation of skin organ cultures with anti-TNF alpha antibodies or the mast cell inhibitor cromolyn sodium abrogated the ability to induce alpha 6 integrins on LC consequent to experimental mast cell degranulation by substance P.	Cromolyn Sodium	108-123	tachykinin precursor 1	Homo sapiens	234-245
7687104-9	1993	Disodium cromoglycate blocked the release of histamine and PGD2.	Cromolyn Sodium	0-21	prostaglandin D2 synthase	Homo sapiens	59-63
8117555-0	1993	Sodium cromoglycate: a remedy for ACE inhibitor-induced cough.	Cromolyn Sodium	0-19	angiotensin I converting enzyme	Homo sapiens	34-37
8117555-4	1993	Inhaled sodium cromoglycate may thus be of value in a proportion of patients with ACE inhibitor-induced cough.	Cromolyn Sodium	8-27	angiotensin I converting enzyme	Homo sapiens	82-85
8509579-5	1993	The LAR after beclomethasone (7.3% +/- 6.1%) was significantly less than after cromolyn (20.4% +/- 15.2%) or placebo (26.4% +/- 8.2%); cromolyn was not different from placebo.	Cromolyn Sodium	135-143	protein tyrosine phosphatase receptor type F	Homo sapiens	4-7
7683300-6	1993	Histamine release in the presence of rIL-3 was inhibited by TYB-2285 and disodium cromoglycate (DSCG) in a dose-dependent manner (1-100 microM).	Cromolyn Sodium	96-100	interleukin 3	Rattus norvegicus	37-42
1625637-0	1992	Sodium cromoglycate for ACE inhibitor cough.	Cromolyn Sodium	0-19	angiotensin I converting enzyme	Homo sapiens	24-27
1285503-10	1992	ECP and PMN elastase concentrations of intratracheal lavage fluids gradually decreased with the DSCG treatment.	Cromolyn Sodium	96-100	elastase, neutrophil expressed	Homo sapiens	8-20
1284281-0	1992	A tiaramide derivative, 5-chloro-3-(4-hydroxypiperadinocarbonylmethyl)benzothiazoline-2-one (HPR-611), a potent inhibitor of anaphylactic chemical mediator release--a distinctive feature from disodium cromoglycate.	Cromolyn Sodium	192-213	haptoglobin-related protein	Homo sapiens	93-96
8364435-0	1993	[Clinical evaluation of disodium cromoglycate with beta-2-agonist in therapy of patients with atopic bronchial asthma (preliminary study)].	Cromolyn Sodium	24-45	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	51-57
1285567-3	1992	In addition, the effects of administration of oral sodium cromoglycate (SCG) on the Copro-IgE levels were studied.	Cromolyn Sodium	51-70	immunoglobulin heavy constant epsilon	Homo sapiens	90-93
1280087-4	1992	Pretreatment with the LTB4 antagonist decreased substance P-induced neutrophil and eosinophil infiltrations in mouse skin at 6 h to the same extent that an inhibitor of mast cell degranulation disodium cromoglycate decreased those responses.	Cromolyn Sodium	193-214	tachykinin 1	Mus musculus	48-59
1583254-12	1992	These effects are likely to be related to the direct action of DSCG on cells bearing the Fc epsilon receptor II and might be independent of the specific trigger.	Cromolyn Sodium	63-67	Fc epsilon receptor II	Homo sapiens	89-111
1588877-0	1992	Sodium cromoglycate for ACE inhibitor cough.	Cromolyn Sodium	0-19	angiotensin I converting enzyme	Homo sapiens	24-27
1630544-2	1992	These drugs are known to ameliorate urinary abnormalities and histological lesions of IgAN associated with ulcerative colitis or Crohn"s disease [5-aminosalicylic acid (5-ASA)] or to prevent, in mice, the induction of IgAN-like disease by oral immunization [disodium cromoglycate (SCG)].	Cromolyn Sodium	258-279	IGAN1	Homo sapiens	86-90
1630544-2	1992	These drugs are known to ameliorate urinary abnormalities and histological lesions of IgAN associated with ulcerative colitis or Crohn"s disease [5-aminosalicylic acid (5-ASA)] or to prevent, in mice, the induction of IgAN-like disease by oral immunization [disodium cromoglycate (SCG)].	Cromolyn Sodium	281-284	IGAN1	Homo sapiens	86-90
1959432-0	1991	Cromolyn for cough due to angiotensin-converting enzyme inhibitor therapy.	Cromolyn Sodium	0-8	angiotensin I converting enzyme	Homo sapiens	26-55
2163279-11	1990	Nedocromil sodium and sodium cromoglycate were equally active as the PAF antagonist BN 52021 in inhibiting the PAF-induced chemotaxis of neutrophils (IC50 approximately 10(-8) M).	Cromolyn Sodium	22-41	PCNA clamp associated factor	Homo sapiens	111-114
1904324-0	1991	Disodium cromoglycate (DSCG) selectively inhibits IgE production and enhances IgG4 production by human B cell in vitro.	Cromolyn Sodium	0-21	immunoglobulin heavy constant epsilon	Homo sapiens	50-53
1904324-0	1991	Disodium cromoglycate (DSCG) selectively inhibits IgE production and enhances IgG4 production by human B cell in vitro.	Cromolyn Sodium	23-27	immunoglobulin heavy constant epsilon	Homo sapiens	50-53
1904324-2	1991	DSCG selectively inhibited interleukin-4 (IL-4) induced IgE production by mononuclear cells (MNC) from normal donors without affecting IgM, IgA, IgG1, IgG2 or IgG3 production.	Cromolyn Sodium	0-4	interleukin 4	Homo sapiens	27-40
1904324-2	1991	DSCG selectively inhibited interleukin-4 (IL-4) induced IgE production by mononuclear cells (MNC) from normal donors without affecting IgM, IgA, IgG1, IgG2 or IgG3 production.	Cromolyn Sodium	0-4	interleukin 4	Homo sapiens	42-46
1904324-2	1991	DSCG selectively inhibited interleukin-4 (IL-4) induced IgE production by mononuclear cells (MNC) from normal donors without affecting IgM, IgA, IgG1, IgG2 or IgG3 production.	Cromolyn Sodium	0-4	immunoglobulin heavy constant epsilon	Homo sapiens	56-59
1904324-2	1991	DSCG selectively inhibited interleukin-4 (IL-4) induced IgE production by mononuclear cells (MNC) from normal donors without affecting IgM, IgA, IgG1, IgG2 or IgG3 production.	Cromolyn Sodium	0-4	immunoglobulin heavy constant gamma 3 (G3m marker)	Homo sapiens	159-163
1904324-7	1991	DSCG also selectively inhibited spontaneous IgE production and enhanced IgG4 production by B cells from atopic patients in the presence of T cells and monocytes.	Cromolyn Sodium	0-4	immunoglobulin heavy constant epsilon	Homo sapiens	44-47
1904400-2	1991	DSCG enhanced IgM, IgG1, IgG2, IgG3, IgG4 and IgA production in a dose-dependent fashion, while DSCG failed to induce IgE production at any concentrations tested by purified B cells.	Cromolyn Sodium	0-4	immunoglobulin heavy constant gamma 3 (G3m marker)	Homo sapiens	31-35
2023992-3	1991	Histamine appears to mediate neurotensin-induced hypothermia because the mast cell stabilizer disodium cromoglycate and antihistamines blocked the hypothermic effects of neurotensin.	Cromolyn Sodium	94-115	neurotensin	Rattus norvegicus	29-40
2023992-3	1991	Histamine appears to mediate neurotensin-induced hypothermia because the mast cell stabilizer disodium cromoglycate and antihistamines blocked the hypothermic effects of neurotensin.	Cromolyn Sodium	94-115	neurotensin	Rattus norvegicus	170-181
1904400-8	1991	DSCG also enhanced IgG2 and IgM production from human B-cell lines GM-1500 and CBL, respectively.	Cromolyn Sodium	0-4	Cbl proto-oncogene	Homo sapiens	79-82
1713735-7	1991	Mast cells were significantly more sensitive to vancomycin and CP 48/80 than RBL-1 cells and, unlike RBL-1 cells, were responsive to the inhibitory effects of cromolyn sodium on histamine release.	Cromolyn Sodium	159-174	RB transcriptional corepressor like 1	Rattus norvegicus	77-82
1690249-8	1990	Furthermore, preincubation of explants with analogue or with the mast cell inhibitor, cromolyn sodium, abrogated the ability of substance P to induce ELAM-1.	Cromolyn Sodium	86-101	tachykinin precursor 1	Homo sapiens	128-139
1903198-7	1991	A 20 mg dose of nebulized cromolyn sodium was used as a test dose in infants, after which urine was collected for 4 hours.	Cromolyn Sodium	26-41	immunoglobulin kappa variable 1-27	Homo sapiens	0-4
2111960-0	1990	The effect of sodium cromoglycate on the induction of experimental IgA nephropathy.	Cromolyn Sodium	14-33	immunoglobulin heavy constant alpha	Mus musculus	67-70
2111960-1	1990	Mesangial IgA nephropathy was experimentally induced in ddY mice by oral and parenteral administration of the poliomyelitis vaccine (POLIO), and we then tried to investigate if IgA deposition could be prevented by the concurrent use of sodium cromoglycate (SCG), which is known to inhibit the local mucosal immune reaction.	Cromolyn Sodium	236-255	immunoglobulin heavy constant alpha	Mus musculus	177-180
1690249-8	1990	Furthermore, preincubation of explants with analogue or with the mast cell inhibitor, cromolyn sodium, abrogated the ability of substance P to induce ELAM-1.	Cromolyn Sodium	86-101	selectin E	Homo sapiens	150-156
2367981-6	1990	The antiallergic drugs ketotifen and sodium cromoglycate (intal) caused a 30-40% inhibition of PAF-induced aggregation of asthmatics" and healthy donors" platelets.	Cromolyn Sodium	37-56	PCNA clamp associated factor	Homo sapiens	95-98
34772945-5	2021	Subsequent treatment with cromolyn and F-cromolyn resulted in reduced secretion of collagen XVIII, fibronectin, and tenascin-c.	Cromolyn Sodium	26-34	collagen type XVIII alpha 1 chain	Homo sapiens	83-97
34772945-5	2021	Subsequent treatment with cromolyn and F-cromolyn resulted in reduced secretion of collagen XVIII, fibronectin, and tenascin-c.	Cromolyn Sodium	26-34	fibronectin 1	Homo sapiens	99-110
34772945-5	2021	Subsequent treatment with cromolyn and F-cromolyn resulted in reduced secretion of collagen XVIII, fibronectin, and tenascin-c.	Cromolyn Sodium	26-34	tenascin C	Homo sapiens	116-126
34772945-6	2021	Additionally, we show that cromolyn and F-cromolyn reduce pro-inflammatory proteins PLP1, PELP1, HSP90, IL-2, GRO-alpha, Eotaxin, and VEGF-Alpha, while promoting secretion of anti-inflammatory IL-4 in HMC3 microglia.	Cromolyn Sodium	27-35	proteolipid protein 1	Homo sapiens	84-88
34772945-6	2021	Additionally, we show that cromolyn and F-cromolyn reduce pro-inflammatory proteins PLP1, PELP1, HSP90, IL-2, GRO-alpha, Eotaxin, and VEGF-Alpha, while promoting secretion of anti-inflammatory IL-4 in HMC3 microglia.	Cromolyn Sodium	27-35	proline, glutamate and leucine rich protein 1	Homo sapiens	90-95
34772945-6	2021	Additionally, we show that cromolyn and F-cromolyn reduce pro-inflammatory proteins PLP1, PELP1, HSP90, IL-2, GRO-alpha, Eotaxin, and VEGF-Alpha, while promoting secretion of anti-inflammatory IL-4 in HMC3 microglia.	Cromolyn Sodium	27-35	heat shock protein 90 alpha family class A member 1	Homo sapiens	97-102
34772945-6	2021	Additionally, we show that cromolyn and F-cromolyn reduce pro-inflammatory proteins PLP1, PELP1, HSP90, IL-2, GRO-alpha, Eotaxin, and VEGF-Alpha, while promoting secretion of anti-inflammatory IL-4 in HMC3 microglia.	Cromolyn Sodium	27-35	interleukin 2	Homo sapiens	104-108
34772945-6	2021	Additionally, we show that cromolyn and F-cromolyn reduce pro-inflammatory proteins PLP1, PELP1, HSP90, IL-2, GRO-alpha, Eotaxin, and VEGF-Alpha, while promoting secretion of anti-inflammatory IL-4 in HMC3 microglia.	Cromolyn Sodium	27-35	C-X-C motif chemokine ligand 1	Homo sapiens	110-119
34772945-6	2021	Additionally, we show that cromolyn and F-cromolyn reduce pro-inflammatory proteins PLP1, PELP1, HSP90, IL-2, GRO-alpha, Eotaxin, and VEGF-Alpha, while promoting secretion of anti-inflammatory IL-4 in HMC3 microglia.	Cromolyn Sodium	27-35	C-C motif chemokine ligand 11	Homo sapiens	121-128
34772945-6	2021	Additionally, we show that cromolyn and F-cromolyn reduce pro-inflammatory proteins PLP1, PELP1, HSP90, IL-2, GRO-alpha, Eotaxin, and VEGF-Alpha, while promoting secretion of anti-inflammatory IL-4 in HMC3 microglia.	Cromolyn Sodium	27-35	interleukin 4	Homo sapiens	193-197
34772945-10	2021	We propose the cromolyn platform targets multiple proteins upstream of PI3K/Akt/mTOR, NF-kappaB, and GSK-3beta signaling pathways to affect cytokine, chemokine, and fibrosis-related protein expression.	Cromolyn Sodium	15-23	AKT serine/threonine kinase 1	Homo sapiens	76-79
34772945-10	2021	We propose the cromolyn platform targets multiple proteins upstream of PI3K/Akt/mTOR, NF-kappaB, and GSK-3beta signaling pathways to affect cytokine, chemokine, and fibrosis-related protein expression.	Cromolyn Sodium	15-23	mechanistic target of rapamycin kinase	Homo sapiens	80-84
34772945-10	2021	We propose the cromolyn platform targets multiple proteins upstream of PI3K/Akt/mTOR, NF-kappaB, and GSK-3beta signaling pathways to affect cytokine, chemokine, and fibrosis-related protein expression.	Cromolyn Sodium	15-23	glycogen synthase kinase 3 alpha	Homo sapiens	101-110
2482349-9	1989	Cinnarizine and nifedipine, calcium channel blockers, and oxatomide, KC-404, tranilast and disodium cromoglycate, anti-allergic agents, also inhibited the PLA2-induced histamine release.	Cromolyn Sodium	91-112	phospholipase A2 group IB	Rattus norvegicus	155-159
35496898-1	2022	Cromolyn sodium (CS) is a mast cell stabilizer administered to treat allergic diseases.	Cromolyn Sodium	0-15	citrate synthase	Homo sapiens	17-19
35114312-9	2022	Additionally, SCG or VAL could reduce the accumulation of ADV in the renal interstitium by upregulating the expression of Oat1/3 and multidrug resistance-associated protein 4.	Cromolyn Sodium	14-17	solute carrier family 22 member 6	Rattus norvegicus	122-128
35114312-9	2022	Additionally, SCG or VAL could reduce the accumulation of ADV in the renal interstitium by upregulating the expression of Oat1/3 and multidrug resistance-associated protein 4.	Cromolyn Sodium	14-17	ATP binding cassette subfamily C member 4	Rattus norvegicus	133-174
35278626-4	2022	METHODS: The in vitro effects of CS on IgE-activated human and mouse MCs were assessed by measuring the levels of pro-inflammatory (tryptase, LTC4, IL-8, CD48) and pro-resolution effectors (IL-10, CD300a, Annexin A1) before and after CS treatment.	Cromolyn Sodium	234-236	citrate synthase	Homo sapiens	33-35
35278626-7	2022	RESULTS: In vitro, CS did not affect pro-inflammatory effectors but significantly increased the anti-inflammatory/pro-resolution CD300a levels and IL-10 release from IgE-activated CBMCs.	Cromolyn Sodium	19-21	CD300A molecule	Mus musculus	129-135
35278626-7	2022	RESULTS: In vitro, CS did not affect pro-inflammatory effectors but significantly increased the anti-inflammatory/pro-resolution CD300a levels and IL-10 release from IgE-activated CBMCs.	Cromolyn Sodium	19-21	interleukin 10	Mus musculus	147-152
35278626-10	2022	CS reduced EPX release from PAF-activated BMEos in vitro, possibly explaining the in vivo findings.	Cromolyn Sodium	0-2	eosinophil peroxidase	Mus musculus	11-14
2547408-10	1989	Both nedocromil sodium (4 mg) and sodium cromoglycate (10 mg) gave significant protection (P less than 0.05) against bradykinin-induced bronchoconstriction (PD40 0.37: 0.19-0.72 mumol after nedocromil sodium and 0.22: 0.11-0.49 after sodium cromoglycate).	Cromolyn Sodium	34-53	kininogen 1	Homo sapiens	117-127
2547408-12	1989	Since bradykinin-induced bronchoconstriction is probably neurally mediated we conclude that both nedocromil sodium and sodium cromoglycate have an action on neural pathways which may be useful in the control of asthma symptoms.	Cromolyn Sodium	119-138	kininogen 1	Homo sapiens	6-16
34198933-0	2021	Scaffold Hopping of alpha-Rubromycin Enables Direct Access to FDA-Approved Cromoglicic Acid as a SARS-CoV-2 MPro Inhibitor.	Cromolyn Sodium	75-91	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	108-112
34198933-8	2021	As a result, cromoglicic acid (aka cromolyn) was found to be the best hit, which, upon in vitro MPro testing, was 4.5 times more potent (IC50 = 1.1 microM and Ki = 0.68 microM) than alpha-rubromycin, with minimal cytotoxicity toward normal human fibroblasts (CC50 > 100 microM).	Cromolyn Sodium	13-29	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	96-100
34198933-8	2021	As a result, cromoglicic acid (aka cromolyn) was found to be the best hit, which, upon in vitro MPro testing, was 4.5 times more potent (IC50 = 1.1 microM and Ki = 0.68 microM) than alpha-rubromycin, with minimal cytotoxicity toward normal human fibroblasts (CC50 > 100 microM).	Cromolyn Sodium	35-43	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	96-100
2511823-0	1989	[Study on the effect of disodium cromoglycate (DSCG) on antigen induced IL-2 responsiveness].	Cromolyn Sodium	24-45	interleukin 2	Homo sapiens	72-76
2511823-0	1989	[Study on the effect of disodium cromoglycate (DSCG) on antigen induced IL-2 responsiveness].	Cromolyn Sodium	47-51	interleukin 2	Homo sapiens	72-76
2511823-1	1989	We tested the effects of disodium cromoglycate (DSCG) on antigen-induced IL-2 responsiveness in lymphocytes from patients with atopic dermatitis and/or bronchial asthma.	Cromolyn Sodium	25-46	interleukin 2	Homo sapiens	73-77
2511823-1	1989	We tested the effects of disodium cromoglycate (DSCG) on antigen-induced IL-2 responsiveness in lymphocytes from patients with atopic dermatitis and/or bronchial asthma.	Cromolyn Sodium	48-52	interleukin 2	Homo sapiens	73-77
2511823-3	1989	DSCG-treated adherent cells were blocked to present the antigen to nonadherent responding cells for induction of IL-2 responsiveness.	Cromolyn Sodium	0-4	interleukin 2	Homo sapiens	113-117
2511823-4	1989	In contrast, DSCG-treated non-adherent cells, recombined with antigen-activated adherent cells, acquired IL-2 responsiveness.	Cromolyn Sodium	13-17	interleukin 2	Homo sapiens	105-109
2511823-6	1989	The results indicate that DSCG is capable of suppressing antigen-induced IL-2 responsiveness but not the response induced by mitogen such as Con A.	Cromolyn Sodium	26-30	interleukin 2	Homo sapiens	73-77
2551444-5	1989	The inhibitory effects of nedocromil sodium, the Paf antagonist BN 52021 and sodium cromoglycate on Paf- and ZAS-induced neutrophil chemotaxis were evaluated.	Cromolyn Sodium	77-96	PCNA clamp associated factor	Homo sapiens	100-103
2547408-0	1989	Bradykinin-induced bronchoconstriction: inhibition by nedocromil sodium and sodium cromoglycate.	Cromolyn Sodium	76-95	kininogen 1	Homo sapiens	0-10
2554440-0	1989	Inhibition of fog-induced bronchoconstriction by nedocromil sodium and sodium cromoglycate in intrinsic asthma: a double-blind, placebo-controlled study.	Cromolyn Sodium	71-90	zinc finger protein, FOG family member 1	Homo sapiens	14-17
2547564-0	1989	Action of nedocromil sodium and sodium cromoglycate on cloned human allergen-specific CD4+ T lymphocytes.	Cromolyn Sodium	32-51	CD4 molecule	Homo sapiens	86-89
2469022-8	1988	Cromoglycate and benzalkoniumchloride, a 48/80 antagonist, both produced a progressive dose-dependent inhibition of beta-endorphin-, neurotensin- as well as compound 48/80-induced histamine release.	Cromolyn Sodium	0-12	neurotensin	Rattus norvegicus	133-144
2554440-3	1989	Statistically significant drug effects (p less than 0.05) were observed after 120 s of fog challenge: both nedocromil sodium 4 and 8 mg and sodium cromoglycate were significantly more effective than placebo in inhibiting fog-induced bronchoconstriction; in addition, nedocromil sodium 4 mg proved statistically significantly more effective than sodium cromoglycate.	Cromolyn Sodium	140-159	zinc finger protein, FOG family member 1	Homo sapiens	87-90
2554440-3	1989	Statistically significant drug effects (p less than 0.05) were observed after 120 s of fog challenge: both nedocromil sodium 4 and 8 mg and sodium cromoglycate were significantly more effective than placebo in inhibiting fog-induced bronchoconstriction; in addition, nedocromil sodium 4 mg proved statistically significantly more effective than sodium cromoglycate.	Cromolyn Sodium	140-159	zinc finger protein, FOG family member 1	Homo sapiens	221-224
2554440-3	1989	Statistically significant drug effects (p less than 0.05) were observed after 120 s of fog challenge: both nedocromil sodium 4 and 8 mg and sodium cromoglycate were significantly more effective than placebo in inhibiting fog-induced bronchoconstriction; in addition, nedocromil sodium 4 mg proved statistically significantly more effective than sodium cromoglycate.	Cromolyn Sodium	345-364	zinc finger protein, FOG family member 1	Homo sapiens	221-224
2847986-4	1988	Preincubation of purified neutrophils or eosinophils with nedocromil sodium or cromolyn partially inhibited their ability to mediate ADCC when stimulated by GM-CSF or TNF.	Cromolyn Sodium	79-87	colony stimulating factor 2	Homo sapiens	157-163
2461668-9	1988	Sodium cromoglycate and nedocromil sodium, 2 drugs that can inhibit mediator release from inflammatory cells, significantly reduced the bronchoconstrictor action of NKA.	Cromolyn Sodium	0-19	tachykinin precursor 1	Homo sapiens	165-168
3134808-2	1988	The protective effect of different doses of sodium cromoglycate (4 mg, 12 mg and 20 mg) given as pressurized aerosol on fog-induced bronchoconstriction were investigated in three different groups of asthmatic patients.	Cromolyn Sodium	44-63	zinc finger protein, FOG family member 1	Homo sapiens	120-123
3134808-5	1988	Sodium cromoglycate effectively prevents fog-induced bronchoconstriction with a clear dose-dependent effect.	Cromolyn Sodium	0-19	zinc finger protein, FOG family member 1	Homo sapiens	41-44
3144513-5	1988	Blood eosinophil counts were unaffected by the challenge whereas the ECP levels were significantly reduced after the placebo challenge and when premedicated with disodium cromoglycate and terbutaline.	Cromolyn Sodium	162-183	ribonuclease A family member 3	Homo sapiens	69-72
3141303-0	1988	Effect of disodium cromoglycate on inflammatory cells bearing the Fc epsilon receptor type II (Fc epsilon RII).	Cromolyn Sodium	10-31	Fc epsilon receptor II	Homo sapiens	95-109
2466315-0	1988	Bronchospasm induced by inhalation of substance P: effect of sodium cromoglycate.	Cromolyn Sodium	61-80	tachykinin precursor 1	Homo sapiens	38-49
2847986-4	1988	Preincubation of purified neutrophils or eosinophils with nedocromil sodium or cromolyn partially inhibited their ability to mediate ADCC when stimulated by GM-CSF or TNF.	Cromolyn Sodium	79-87	tumor necrosis factor	Homo sapiens	167-170
3368638-6	1988	These results, as well as the efficacy of treatment with disodium cromoglycate, suggest that an IgE mechanism is involved in the pathogenesis of this occupational asthma.	Cromolyn Sodium	57-78	immunoglobulin heavy constant epsilon	Homo sapiens	96-99
3130088-3	1987	An early peak concentration of sodium cromoglycate occurred in the plasma, thereafter the plasma concentration declined mono- or bi-exponentially with a terminal T1/2 of approximately 100 minutes in both patients and normal subjects.	Cromolyn Sodium	31-50	CD6 molecule	Homo sapiens	162-187
3125594-4	1987	Both the symptoms and the appearance of IgE immune complexes could be prevented by pretreatment with oral sodium cromoglycate (SCG).	Cromolyn Sodium	106-125	immunoglobulin heavy constant epsilon	Homo sapiens	40-43
3135817-2	1987	The specific cromolyn binding protein (CBP) has been isolated by using its high affinity form cromolyn.	Cromolyn Sodium	13-21	CREB binding protein	Rattus norvegicus	39-42
3936652-4	1985	Maximal CRE with the rosette method was observed at 30 min, whereas increased uptake of anti-CR1 had still not reached a plateau after 1 h. DSCG inhibited fMLP-induced CRE, as assessed by the rosette technique, whereas this agent had no effect on increased binding of radio-labelled anti-CR1 antibody.	Cromolyn Sodium	140-144	complement C3b/C4b receptor 1 (Knops blood group)	Homo sapiens	93-96
2940951-3	1986	Those cultured in cromolyn exhibited a significantly decreased A23187- or antigen-induced release of beta-hexosaminidase (4.3 +/- 0.7% versus 9.2 +/- 1.0%, p less than 0.01) compared with control cells.	Cromolyn Sodium	18-26	O-GlcNAcase	Mus musculus	101-120
2425573-2	1986	The release is dependent on FMLP concentration and it can be inhibited by disodium cromoglycate and by a flavonoid, silymarin, which displays free radical scavenging properties.	Cromolyn Sodium	74-95	formyl peptide receptor 1	Homo sapiens	28-32
2424843-0	1986	Neurotensin stimulates histamine release in in vivo skin "blisters" in rats: an effect inhibited by cromolyn or somatostatin.	Cromolyn Sodium	100-108	neurotensin	Rattus norvegicus	0-11
3541715-9	1987	Likewise, cromolyn sodium (40 mg dry powder) also significantly reduced response to bradykinin, with a PD35 of 0.04 mumol (range, 0.13 to 0.31) after placebo and 0.39 mumol (range, 0.05 to 4.45) after SCG (p less than 0.05).	Cromolyn Sodium	10-25	kininogen 1	Homo sapiens	84-94
3114658-1	1987	We recently reported on an experimentally induced model of IgA nephropathy in mice by long-term oral immunization under the reticuloendothelial dysfunction, which was found to be effectively inhibited by the administration of the antiallergic agent sodium cromoglycate (SCG).	Cromolyn Sodium	249-268	immunoglobulin heavy constant alpha	Mus musculus	59-62
3937847-3	1985	This literature review provides a foundation for understanding the balance between the therapeutic efficacy, clinical benefits and side effects in treating IgE-mediated conjunctivitis with disodium cromoglycate.	Cromolyn Sodium	189-210	immunoglobulin heavy constant epsilon	Homo sapiens	156-159
3936652-4	1985	Maximal CRE with the rosette method was observed at 30 min, whereas increased uptake of anti-CR1 had still not reached a plateau after 1 h. DSCG inhibited fMLP-induced CRE, as assessed by the rosette technique, whereas this agent had no effect on increased binding of radio-labelled anti-CR1 antibody.	Cromolyn Sodium	140-144	formyl peptide receptor 1	Homo sapiens	155-159
3936652-4	1985	Maximal CRE with the rosette method was observed at 30 min, whereas increased uptake of anti-CR1 had still not reached a plateau after 1 h. DSCG inhibited fMLP-induced CRE, as assessed by the rosette technique, whereas this agent had no effect on increased binding of radio-labelled anti-CR1 antibody.	Cromolyn Sodium	140-144	complement C3b/C4b receptor 1 (Knops blood group)	Homo sapiens	288-291
3923788-0	1985	Actions of disodium cromoglycate (DSCG) on human skin responses to histamine, codeine and Paf-acether.	Cromolyn Sodium	11-32	PCNA clamp associated factor	Homo sapiens	90-93
3923788-0	1985	Actions of disodium cromoglycate (DSCG) on human skin responses to histamine, codeine and Paf-acether.	Cromolyn Sodium	34-38	PCNA clamp associated factor	Homo sapiens	90-93
3922643-0	1985	Effect of disodium cromoglycate on anti-IgE induced early and late skin response in humans.	Cromolyn Sodium	10-31	immunoglobulin heavy constant epsilon	Homo sapiens	40-43
3922643-1	1985	The effect of the anti-allergic drug disodium cromoglycate (DSCG) on immediate and late responses to anti-human IgE was examined in thirteen healthy subjects.	Cromolyn Sodium	37-58	immunoglobulin heavy constant epsilon	Homo sapiens	112-115
3922643-1	1985	The effect of the anti-allergic drug disodium cromoglycate (DSCG) on immediate and late responses to anti-human IgE was examined in thirteen healthy subjects.	Cromolyn Sodium	60-64	immunoglobulin heavy constant epsilon	Homo sapiens	112-115
2409026-9	1985	Sodium cromoglycate partially inhibited the airway and plasma histamine responses with antigen, but totally inhibited the increases in NCF.	Cromolyn Sodium	0-19	neutrophil cytosolic factor 4	Homo sapiens	135-138
6577465-11	1983	The restored capacity is due to the implanted CBP, because the reinstated immunological response can be blocked by the inhibitory drug cromolyn and by monoclonal antibodies specific to CBP, both shown to prevent Ca(2+) uptake and degranulation in mast cells and parental RBL-2H3 cells.	Cromolyn Sodium	135-143	CREB binding protein	Rattus norvegicus	46-49
6205239-6	1984	The mast cell inhibitor cromoglycate markedly inhibited NT-induced histamine release without affecting the coronary vasoconstrictor effect of NT.	Cromolyn Sodium	24-36	neurotensin	Rattus norvegicus	56-58
6439565-0	1984	Effect of disodium chromoglycate on changes in nasal airway resistance induced by platelet activating factor.	Cromolyn Sodium	10-32	PCNA clamp associated factor	Homo sapiens	82-108
6439565-4	1984	Pretreatment with disodium chromoglycate blocked the decrease in nasal airway resistance induced by PAF.	Cromolyn Sodium	18-40	PCNA clamp associated factor	Homo sapiens	100-103
6415824-6	1983	Once a patient"s asthma has been stabilized, sodium cromoglycate enables concomitant therapy (especially with beta 2-adrenergic stimulants and corticosteroids) to be reduced.	Cromolyn Sodium	45-64	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	110-116
2417943-6	1985	Preincubation of mast cells with calcium ion chelating agent ethylenediaminetetraacetic acid (EDTA) or disodium cromoglycate induces only a small inhibition of histamine release caused by HRF.	Cromolyn Sodium	103-124	endothelial PAS domain protein 1	Mus musculus	188-191
6093125-3	1984	These studies identify the Ca2+ channel-forming membrane component as the cromolyn binding protein [CBP, in which cromolyn is the anti-asthmatic drug 1,3-bis(2-carboxy-chromon-5-yloxy)-2-hydroxypropane].	Cromolyn Sodium	74-82	CREB binding protein	Rattus norvegicus	100-103
6093125-3	1984	These studies identify the Ca2+ channel-forming membrane component as the cromolyn binding protein [CBP, in which cromolyn is the anti-asthmatic drug 1,3-bis(2-carboxy-chromon-5-yloxy)-2-hydroxypropane].	Cromolyn Sodium	114-122	CREB binding protein	Rattus norvegicus	100-103
6093125-3	1984	These studies identify the Ca2+ channel-forming membrane component as the cromolyn binding protein [CBP, in which cromolyn is the anti-asthmatic drug 1,3-bis(2-carboxy-chromon-5-yloxy)-2-hydroxypropane].	Cromolyn Sodium	150-201	CREB binding protein	Rattus norvegicus	100-103
6405112-2	1983	Treatment of animals with compound 48/80 or disodium cromoglycate completely inhibited the elevation of histamine level by NT, however, treatment with reserpine or diphenhydramine and adrenalectomy did not affect the elevation.	Cromolyn Sodium	44-65	neurotensin	Rattus norvegicus	123-125
6406905-2	1983	We have demonstrated the presence of specific binding sites for that drug on the membranes of basophils and mast cells and more recently, we have succeeded in isolating the cromoglycate-binding protein from the membranes of RBL-2H3 cells.	Cromolyn Sodium	173-185	RB transcriptional corepressor like 2	Rattus norvegicus	224-229
6406905-4	1983	To further investigate this, we have selected variants of the RBL-2H3 cell line that are defective in cromoglycate binding but bind IgE normally.	Cromolyn Sodium	102-114	RB transcriptional corepressor like 2	Rattus norvegicus	62-67
6189542-1	1983	1 Three drugs have been tested for activity against antigen-induced histamine release from passively sensitized human lung fragments after increasing periods of pre-incubation before challenge.2 After 30 s pre-incubation, sodium cromoglycate inhibited histamine release in the concentration range 0.2-200 muM, producing a maximum inhibition of 33.0%.	Cromolyn Sodium	222-241	latexin	Homo sapiens	305-308
6401928-3	1983	Of 16 patients with ragweed IgE values of less than 100 ng/ml, the nine treated with cromolyn had significantly fewer symptoms during the course of treatment than the seven in the placebo group.	Cromolyn Sodium	85-93	immunoglobulin heavy constant epsilon	Homo sapiens	28-31
6401928-4	1983	Of the 15 remaining patients, who had IgE levels of more than 100 ng/ml, the eight treated with cromolyn improved but the difference between their symptom scores and those of the seven patients treated with placebo was not statistically significant.	Cromolyn Sodium	96-104	immunoglobulin heavy constant epsilon	Homo sapiens	38-41
6403977-3	1983	After 30 days treatment with sodium cromoglycate, there was a significant reduction in response to fog challenge, compared with pretreatment values.	Cromolyn Sodium	29-48	zinc finger protein, FOG family member 1	Homo sapiens	99-102
6183024-3	1982	The release of NCF was inhibited by prior administration of disodium cromoglycate (DSCG) suggesting its possible mast cell origin.	Cromolyn Sodium	60-81	neutrophil cytosolic factor 4	Homo sapiens	15-18
6183024-3	1982	The release of NCF was inhibited by prior administration of disodium cromoglycate (DSCG) suggesting its possible mast cell origin.	Cromolyn Sodium	83-87	neutrophil cytosolic factor 4	Homo sapiens	15-18
6125747-0	1982	Asthma attacks precipitated by disodium cromoglycate in boy with alpha 1-antitrypsin deficiency.	Cromolyn Sodium	31-52	serpin family A member 1	Homo sapiens	65-84
6808133-1	1982	Several known antiallergic agents, including cromolyn sodium and a series of pyrido[2,1-b]quinazolines, inhibit human alkaline phosphatase (ALP), a membranal enzyme associated with calcium uptake in certain tissues.	Cromolyn Sodium	45-60	alkaline phosphatase, placental	Homo sapiens	140-143
6178768-8	1982	The prior administration of cromolyn to three asthmatics inhibited both their EIA and the release of histamine and NCF.	Cromolyn Sodium	28-36	neutrophil cytosolic factor 4	Homo sapiens	115-118
6808133-0	1982	Alkaline phosphatase inhibition by a series of pyrido[2,1-b]quinazolines: A possible relationship with cromolyn-like antiallergy activity.	Cromolyn Sodium	103-111	alkaline phosphatase, placental	Homo sapiens	0-20
6808133-1	1982	Several known antiallergic agents, including cromolyn sodium and a series of pyrido[2,1-b]quinazolines, inhibit human alkaline phosphatase (ALP), a membranal enzyme associated with calcium uptake in certain tissues.	Cromolyn Sodium	45-60	alkaline phosphatase, placental	Homo sapiens	118-138
100592-1	1978	The interaction of the antiasthmatic drug cromolyn sodium with Mg2+ ions in solution was studied.	Cromolyn Sodium	42-57	mucin 7, secreted	Homo sapiens	63-66
6178820-6	1982	The secretory response produced by neurotensin was prevented by prior treatment of mast cells with cromoglycate.	Cromolyn Sodium	99-111	neurotensin	Rattus norvegicus	35-46
6178820-11	1982	The intravenous injection of cromoglycate 1-2 min before neurotensin greatly reduced the response to neurotensin.	Cromolyn Sodium	29-41	neurotensin	Rattus norvegicus	57-68
6178820-11	1982	The intravenous injection of cromoglycate 1-2 min before neurotensin greatly reduced the response to neurotensin.	Cromolyn Sodium	29-41	neurotensin	Rattus norvegicus	101-112
6174350-3	1981	Disodium cromoglycate markedly, but benzalkonium chloride only slightly, inhibited the neurotensin-induced release.	Cromolyn Sodium	0-21	neurotensin	Rattus norvegicus	87-98
6797316-6	1981	In allergic rhinitis some patients showed an initial peak-like increase of serum-ECP, which was abolished by pretreatment with disodium-cromoglycate but not by pretreatment with antihistamine.	Cromolyn Sodium	127-148	ribonuclease A family member 3	Homo sapiens	81-84
6159030-1	1980	1 Eleven analogues of sodium cromoglycate have been tested for their ability to suppress histamine release induced by anti-IgE from passively sensitized human lung fragments in vitro.	Cromolyn Sodium	22-41	immunoglobulin heavy constant epsilon	Homo sapiens	123-126
6769825-2	1980	After treatment with DSCG for 3 days both hepatic and non-hepatic (lipoprotein lipase sensu strictiori) plasma post-heparin lipoprotein lipase activities were significantly depressed.	Cromolyn Sodium	21-25	lipoprotein lipase	Homo sapiens	67-85
6769825-2	1980	After treatment with DSCG for 3 days both hepatic and non-hepatic (lipoprotein lipase sensu strictiori) plasma post-heparin lipoprotein lipase activities were significantly depressed.	Cromolyn Sodium	21-25	lipoprotein lipase	Homo sapiens	124-142
6170594-8	1981	The amylase release induced by norepinephrine, mediated via beta1-adrenoceptor, is depressed by DSCG.	Cromolyn Sodium	96-100	adrenoceptor beta 1	Homo sapiens	60-78
6780413-8	1980	As an IgE-mediated immune mechanism was considered to play a role in this type of proctitis, eight of the 12 patients were treated with oral administration of disodium cromoglycate (DSCG).	Cromolyn Sodium	159-180	immunoglobulin heavy constant epsilon	Homo sapiens	6-9
231532-0	1979	Inhibitory effects of cromoglycate and theophylline on rat macrophage and mast-cell cyclic nucleotide phosphodiesterase [proceedings].	Cromolyn Sodium	22-34	phosphodiesterase 3A	Rattus norvegicus	84-119
4216891-0	1974	[Study of serum IgE during allergic asthmas (except pollinosis), non-allergic asthmas and chronic bronchitis, and of their modification through sodium cromoglycate].	Cromolyn Sodium	144-163	immunoglobulin heavy constant epsilon	Homo sapiens	16-19
824068-1	1976	BRL 10833, a nitroindanedione, with similar inhibitory activities to DSCG on the immediate type IgE mediated hypersensitivity in the rat, has been shown, when inhaled in a dose of 40 mg, to protect against allergen induced bronchospasm.	Cromolyn Sodium	69-73	bromodomain containing 1	Homo sapiens	0-3
406300-0	1977	Preseasonal IgE ragweed antibody level as a predictor of response to therapy of ragweed hay fever with intranasal cromolyn sodium solution.	Cromolyn Sodium	114-129	immunoglobulin heavy constant epsilon	Homo sapiens	12-15
19825-0	1977	Regulation of intracellular cyclic GMP and cyclic AMP levels in mouse lung fragments by disodium cromoglycate, beta-adrenergic agonists, cholinergic activators, and histamine.	Cromolyn Sodium	88-109	5'-nucleotidase, cytosolic II	Mus musculus	35-38
821986-7	1976	In an attempt to differentiate between good and poor cromolyn responders by clinical and laboratory parameters, we found that (1) patients with high IgE levels responded better than those with low IgE levels, (2) patients with markedly positive skin test reactions to epidermoids and to foods responded better than those with pollen allergy, and (3) females appeared to have a significantly better drug response than males.	Cromolyn Sodium	53-61	immunoglobulin heavy constant epsilon	Homo sapiens	149-152
821986-7	1976	In an attempt to differentiate between good and poor cromolyn responders by clinical and laboratory parameters, we found that (1) patients with high IgE levels responded better than those with low IgE levels, (2) patients with markedly positive skin test reactions to epidermoids and to foods responded better than those with pollen allergy, and (3) females appeared to have a significantly better drug response than males.	Cromolyn Sodium	53-61	immunoglobulin heavy constant epsilon	Homo sapiens	197-200
4118943-0	1972	Effect of disodium cromoglycate on phospholipase A activity.	Cromolyn Sodium	10-31	phospholipase A and acyltransferase 1	Mus musculus	35-50
4197023-0	1973	Protection from exercise-induced asthma by pre-exercise cromolyn sodium and its relationship to serum IGE levels.	Cromolyn Sodium	56-71	immunoglobulin heavy constant epsilon	Homo sapiens	102-105
31552201-10	2019	Decreased MCs-derived CCL2, CXCL1, and MMP-9 from CLN and skin, mRNA expression in CLN and liver (TNF-alpha, IFN-gamma, CCR2, and CXCR2) were also observed in infected mice with DSCG treatment.	Cromolyn Sodium	178-182	tumor necrosis factor	Mus musculus	98-107
4183038-0	1969	Disodium cromoglycate, an inhibitor of mas cell degranulation and histamine release induced by phospholipase A.	Cromolyn Sodium	0-21	phospholipase A and acyltransferase 1	Homo sapiens	95-110
33579853-1	2021	BACKGROUND: Cromolyn is an anti-neuroinflammatory modulator with a multifactorial mechanism of action that has been shown to inhibit amyloid-beta (Abeta) aggregation and enhance microglial uptake and clearance of Abeta.	Cromolyn Sodium	12-20	amyloid beta (A4) precursor protein	Mus musculus	147-152
33579853-1	2021	BACKGROUND: Cromolyn is an anti-neuroinflammatory modulator with a multifactorial mechanism of action that has been shown to inhibit amyloid-beta (Abeta) aggregation and enhance microglial uptake and clearance of Abeta.	Cromolyn Sodium	12-20	amyloid beta (A4) precursor protein	Mus musculus	213-218
33579853-12	2021	These findings suggest that a fluoro-cromolyn analog could reduce fibril-prone Abeta 42in vivo and thereby serve as a therapeutic for the treatment and prevention of AD.	Cromolyn Sodium	37-45	amyloid beta (A4) precursor protein	Mus musculus	79-84
33339114-1	2020	Advanced and sensitive spectrophotometric and chemometric analytical methods were successfully established for the stability-indicating assay of cromolyn sodium (CS) and its alkaline degradation products (Deg1 and Deg2).	Cromolyn Sodium	145-160	citrate synthase	Homo sapiens	162-164
806398-4	1975	Sodium cromoglycate impairs all these anti-IgE induced basophil changes, providing further insight into the mechanism of action of this compound in bronchial asthma.	Cromolyn Sodium	0-19	immunoglobulin heavy constant epsilon	Homo sapiens	43-46
33882264-11	2021	Using an immuno-competent Tsc2 null murine homograft model, sodium cromoglycate markedly reduced mast cell activation and Tsc2 null lung tumour burden (vehicle: 32.5.3%+-23.6 and cromoglycate: 5.5%+-4.3.	Cromolyn Sodium	60-79	TSC complex subunit 2	Mus musculus	26-30
33882264-11	2021	Using an immuno-competent Tsc2 null murine homograft model, sodium cromoglycate markedly reduced mast cell activation and Tsc2 null lung tumour burden (vehicle: 32.5.3%+-23.6 and cromoglycate: 5.5%+-4.3.	Cromolyn Sodium	60-79	TSC complex subunit 2	Mus musculus	122-126
33882264-11	2021	Using an immuno-competent Tsc2 null murine homograft model, sodium cromoglycate markedly reduced mast cell activation and Tsc2 null lung tumour burden (vehicle: 32.5.3%+-23.6 and cromoglycate: 5.5%+-4.3.	Cromolyn Sodium	67-79	TSC complex subunit 2	Mus musculus	26-30
33882264-11	2021	Using an immuno-competent Tsc2 null murine homograft model, sodium cromoglycate markedly reduced mast cell activation and Tsc2 null lung tumour burden (vehicle: 32.5.3%+-23.6 and cromoglycate: 5.5%+-4.3.	Cromolyn Sodium	67-79	TSC complex subunit 2	Mus musculus	122-126
33850164-4	2021	The direct effect of cromolyn on HMC3 microglia is on cytokines and chemokines production following their activation by the inflammatory cytokine TNF-alpha.	Cromolyn Sodium	21-29	tumor necrosis factor	Homo sapiens	146-155
33850164-5	2021	Cromolyn and a new fluorinated analog dramatically reduced the secretion of a wide spectrum of inflammatory mediators, which included cytokines such as IL-1beta, IL-6, IL-8 and IFN-gamma, and chemokines such as CXCL10, CCL2, CCL3 and CCL4.	Cromolyn Sodium	0-8	interleukin 1 alpha	Homo sapiens	152-160
33850164-5	2021	Cromolyn and a new fluorinated analog dramatically reduced the secretion of a wide spectrum of inflammatory mediators, which included cytokines such as IL-1beta, IL-6, IL-8 and IFN-gamma, and chemokines such as CXCL10, CCL2, CCL3 and CCL4.	Cromolyn Sodium	0-8	interleukin 6	Homo sapiens	162-166
33850164-5	2021	Cromolyn and a new fluorinated analog dramatically reduced the secretion of a wide spectrum of inflammatory mediators, which included cytokines such as IL-1beta, IL-6, IL-8 and IFN-gamma, and chemokines such as CXCL10, CCL2, CCL3 and CCL4.	Cromolyn Sodium	0-8	C-X-C motif chemokine ligand 8	Homo sapiens	168-172
33850164-5	2021	Cromolyn and a new fluorinated analog dramatically reduced the secretion of a wide spectrum of inflammatory mediators, which included cytokines such as IL-1beta, IL-6, IL-8 and IFN-gamma, and chemokines such as CXCL10, CCL2, CCL3 and CCL4.	Cromolyn Sodium	0-8	interferon gamma	Homo sapiens	177-186
33850164-5	2021	Cromolyn and a new fluorinated analog dramatically reduced the secretion of a wide spectrum of inflammatory mediators, which included cytokines such as IL-1beta, IL-6, IL-8 and IFN-gamma, and chemokines such as CXCL10, CCL2, CCL3 and CCL4.	Cromolyn Sodium	0-8	C-X-C motif chemokine ligand 10	Homo sapiens	211-217
33850164-5	2021	Cromolyn and a new fluorinated analog dramatically reduced the secretion of a wide spectrum of inflammatory mediators, which included cytokines such as IL-1beta, IL-6, IL-8 and IFN-gamma, and chemokines such as CXCL10, CCL2, CCL3 and CCL4.	Cromolyn Sodium	0-8	C-C motif chemokine ligand 2	Homo sapiens	219-223
33850164-5	2021	Cromolyn and a new fluorinated analog dramatically reduced the secretion of a wide spectrum of inflammatory mediators, which included cytokines such as IL-1beta, IL-6, IL-8 and IFN-gamma, and chemokines such as CXCL10, CCL2, CCL3 and CCL4.	Cromolyn Sodium	0-8	C-C motif chemokine ligand 3	Homo sapiens	225-229
33850164-5	2021	Cromolyn and a new fluorinated analog dramatically reduced the secretion of a wide spectrum of inflammatory mediators, which included cytokines such as IL-1beta, IL-6, IL-8 and IFN-gamma, and chemokines such as CXCL10, CCL2, CCL3 and CCL4.	Cromolyn Sodium	0-8	C-C motif chemokine ligand 4	Homo sapiens	234-238
32955722-9	2021	Further, the administration of cromolyn drug significantly inhibited acute TBI-associated decrease of PDGFR-beta, JAM-A, and ZO-1 in the brain.	Cromolyn Sodium	31-39	platelet derived growth factor receptor, alpha polypeptide	Mus musculus	102-112
32955722-9	2021	Further, the administration of cromolyn drug significantly inhibited acute TBI-associated decrease of PDGFR-beta, JAM-A, and ZO-1 in the brain.	Cromolyn Sodium	31-39	F11 receptor	Mus musculus	114-119
32955722-9	2021	Further, the administration of cromolyn drug significantly inhibited acute TBI-associated decrease of PDGFR-beta, JAM-A, and ZO-1 in the brain.	Cromolyn Sodium	31-39	tight junction protein 1	Mus musculus	125-129
33154104-4	2021	In anesthetized mice, mast cell degranulation induced by Compound 48/80 (C48/80) or stabilization by cromolyn enhanced or repressed, respectively, the dose-dependent vasopressor responses to big ET-1 in wild-type (WT) mice but not in mMCP-4 knockout mice in a chymase inhibitor (TY-51469)-sensitive fashion.	Cromolyn Sodium	101-109	endothelin 1	Mus musculus	195-199
33154104-5	2021	In addition, mMCP-4 dependent hydrolysis of the fluorogenic substrate Suc-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin was depleted or enhanced in peritoneal mast cells isolated from mice pre-treated with C48/80 or cromolyn, respectively.	Cromolyn Sodium	211-219	mast cell protease 4	Mus musculus	13-19
33154104-6	2021	Furthermore, C48/80 or cromolyn markedly increased or abolished, respectively, ET-1 (1-31) conversion from exogenous big ET-1 in WT mice peritoneal fluid-isolated mast cells, in vitro.	Cromolyn Sodium	23-31	endothelin 1	Mus musculus	79-83
33154104-6	2021	Furthermore, C48/80 or cromolyn markedly increased or abolished, respectively, ET-1 (1-31) conversion from exogenous big ET-1 in WT mice peritoneal fluid-isolated mast cells, in vitro.	Cromolyn Sodium	23-31	endothelin 1	Mus musculus	121-125
30821650-0	2020	Characterization of interactions between cromolyn sodium and bovine serum albumin by spectroscopic, calorimetric and computational methods.	Cromolyn Sodium	41-56	albumin	Homo sapiens	68-81
31520526-13	2019	Pretreatment with cromoglycate, a stabilizer of MCs, mitigated these HMGB-1-induced pro-inflammatory processes in rats.	Cromolyn Sodium	18-30	high mobility group box 1	Rattus norvegicus	69-75
31189299-2	2019	Furthermore, cromolyn was shown to be a G protein-coupled receptor 35 (GPR35) agonist.	Cromolyn Sodium	13-21	G protein-coupled receptor 35	Mus musculus	40-69
31189299-2	2019	Furthermore, cromolyn was shown to be a G protein-coupled receptor 35 (GPR35) agonist.	Cromolyn Sodium	13-21	G protein-coupled receptor 35	Mus musculus	71-76
30978390-10	2019	DSCG or ketotifen lost their activities in inhibiting LDL-induced activation of MCs from LDL receptor-deficient mice.	Cromolyn Sodium	0-4	low density lipoprotein receptor	Mus musculus	89-101
30115604-3	2018	Our results revealed that animals that received a single dose of CG (50 mg/kg s.c.: subcutaneously) during the post-SE period showed a lower number of neurons in the process of dying in the dentate gyrus, hilus, cornu ammonis 1 (CA1), and CA3 of the dorsal hippocampus than the rats that received the vehicle.	Cromolyn Sodium	65-67	carbonic anhydrase 3	Rattus norvegicus	239-242
31130850-11	2019	Results: In this study, intraperitoneal injection of 1 mg/kg LPS induced mast cell activation in hypothalamus and cognitive dysfunction in rats, and that this process can be repressed by the mast cell stabilizer cromolyn (200 mug).	Cromolyn Sodium	212-220	toll-like receptor 4	Mus musculus	61-64
31130850-14	2019	We also found that LPS selectively provokes upregulation of H1R, H4R, PAR2, and TLR4, but downregulation of H2R and H3R, in ipsilateral hypothalamus microglia; these effects were partially inhibited by cromolyn.	Cromolyn Sodium	202-210	toll-like receptor 4	Mus musculus	19-22
30694039-6	2019	SCG was found to be effective in detecting early isomers of alpha-syn in vitro and in live cell environments.	Cromolyn Sodium	0-3	synuclein alpha	Homo sapiens	60-69
30072157-11	2018	However, these effects of leptin were attenuated by pre-injection of DSCG (25 mg).	Cromolyn Sodium	69-73	leptin	Canis lupus familiaris	26-32
30304698-2	2019	Recently, cromolyn, a mast cell stabilizer, was reported as an agonist of GPR35 and was shown to exhibit antifibrotic effects through its actions on hepatocytes and stellate cells.	Cromolyn Sodium	10-18	G protein-coupled receptor 35	Homo sapiens	74-79
29862868-6	2018	The CS treatment decreased MC degranulation in the liver and reduced serum tryptase (an MC granule component).	Cromolyn Sodium	4-6	tryptase alpha/beta 1	Rattus norvegicus	75-83
28002455-11	2016	We further treated URO-OVA mice with cromolyn, a mast cell membrane stabilizer, and found that cromolyn treatment reversed bladder inflammation and LUTD in the animal model.	Cromolyn Sodium	37-45	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	23-26
29849098-8	2018	Interestingly, pretreatment with cromolyn sodium (Block) significantly blocked MC degranulation, dramatically suppressed vascular dilation and permeability, and markedly reduced neutrophil infiltration with lower ICAM-1 levels in FK mice at 6-24 hours.	Cromolyn Sodium	33-48	intercellular adhesion molecule 1	Mus musculus	213-219
29644714-5	2018	By comparing IC50 (muM) values with that of the standard drug sodium cromoglycate (IC50  = 0.489 +- 0.003 muM), compounds with bulky groups like heptyl (compound 9; IC50  = 0.389 +- 0.015 muM) and octyl (compound 10; IC50  = 0.354 +- 0.023 muM) were found to be of similar potency as sodium cromoglycate.	Cromolyn Sodium	62-81	latexin	Homo sapiens	106-109
29644714-5	2018	By comparing IC50 (muM) values with that of the standard drug sodium cromoglycate (IC50  = 0.489 +- 0.003 muM), compounds with bulky groups like heptyl (compound 9; IC50  = 0.389 +- 0.015 muM) and octyl (compound 10; IC50  = 0.354 +- 0.023 muM) were found to be of similar potency as sodium cromoglycate.	Cromolyn Sodium	62-81	latexin	Homo sapiens	106-109
29644714-5	2018	By comparing IC50 (muM) values with that of the standard drug sodium cromoglycate (IC50  = 0.489 +- 0.003 muM), compounds with bulky groups like heptyl (compound 9; IC50  = 0.389 +- 0.015 muM) and octyl (compound 10; IC50  = 0.354 +- 0.023 muM) were found to be of similar potency as sodium cromoglycate.	Cromolyn Sodium	62-81	latexin	Homo sapiens	106-109
30938257-7	2018	After one-year DSCG treatment, the total IgE levels increased significantly, whereas the levels remained the same during BDP treatment.	Cromolyn Sodium	15-19	immunoglobulin heavy constant epsilon	Homo sapiens	41-44
30938257-8	2018	Five of 22 (23%) patients in the DSCG-treated group became positive for Df-specific IgE; however, only one of 13 (8%) in the BDP-treated group became positive.	Cromolyn Sodium	33-37	immunoglobulin heavy constant epsilon	Homo sapiens	84-87
28824610-11	2017	Moreover, the intracardiac parasite load was significantly reduced in WT mice pretreated with (i) cromoglycate (MC stabilizer) (ii) infestin-4, a specific inhibitor of FXIIa (iii) HOE-140 (specific antagonist of B2R), and (iv) bosentan, a non-selective antagonist of ETAR/ETBR.	Cromolyn Sodium	98-110	bradykinin receptor, beta 2	Mus musculus	212-215
28824610-11	2017	Moreover, the intracardiac parasite load was significantly reduced in WT mice pretreated with (i) cromoglycate (MC stabilizer) (ii) infestin-4, a specific inhibitor of FXIIa (iii) HOE-140 (specific antagonist of B2R), and (iv) bosentan, a non-selective antagonist of ETAR/ETBR.	Cromolyn Sodium	98-110	endothelin receptor type A	Mus musculus	267-271
28824610-11	2017	Moreover, the intracardiac parasite load was significantly reduced in WT mice pretreated with (i) cromoglycate (MC stabilizer) (ii) infestin-4, a specific inhibitor of FXIIa (iii) HOE-140 (specific antagonist of B2R), and (iv) bosentan, a non-selective antagonist of ETAR/ETBR.	Cromolyn Sodium	98-110	endothelin receptor type B	Mus musculus	272-276
28439288-0	2017	Systemic mastocytosis with KIT V560G mutation presenting as recurrent episodes of vascular collapse: response to disodium cromoglycate and disease outcome.	Cromolyn Sodium	113-134	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	27-30
28439288-9	2017	CONCLUSIONS: To the best of our knowledge this first report of a patient with ISM, whose bone marrow MCs carry the KIT V560G activating mutation, manifesting as recurrent spontaneous episodes of flushing and vascular collapse in the absence of skin lesions at the time of diagnosis, in whom disodium cromoglycate had led to long term clinical remission.	Cromolyn Sodium	291-312	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	115-118
29348604-3	2018	Cromolyn sodium is an asthma therapeutic agent previously shown to reduce Abeta levels in transgenic AD mouse brains after one-week of treatment.	Cromolyn Sodium	0-15	amyloid beta (A4) precursor protein	Mus musculus	74-79
29348604-6	2018	Cromolyn, alone, or in combination with ibuprofen, almost completely abolished longer insoluble Abeta species, i.e. Abeta40 and Abeta42, but increased insoluble Abeta38 levels.	Cromolyn Sodium	0-8	amyloid beta (A4) precursor protein	Mus musculus	96-101
29348604-9	2018	Collectively, our data reveal robust effects of cromolyn, alone, or in combination with ibuprofen, in reducing aggregation-prone Abeta levels and inducing a neuroprotective microglial activation state favoring Abeta phagocytosis versus a pro-neuroinflammatory state.	Cromolyn Sodium	48-56	amyloid beta (A4) precursor protein	Mus musculus	129-134
29348604-9	2018	Collectively, our data reveal robust effects of cromolyn, alone, or in combination with ibuprofen, in reducing aggregation-prone Abeta levels and inducing a neuroprotective microglial activation state favoring Abeta phagocytosis versus a pro-neuroinflammatory state.	Cromolyn Sodium	48-56	amyloid beta (A4) precursor protein	Mus musculus	210-215
28561222-8	2017	The results showed that lung HP level as well as IL-1beta, TNF-alpha and IL-8 were significantly lower in the CS treated rats as compared to PQ group.	Cromolyn Sodium	110-112	interleukin 1 beta	Rattus norvegicus	49-57
28561222-8	2017	The results showed that lung HP level as well as IL-1beta, TNF-alpha and IL-8 were significantly lower in the CS treated rats as compared to PQ group.	Cromolyn Sodium	110-112	tumor necrosis factor	Rattus norvegicus	59-68
26797518-5	2017	"Mast cell stabilizer" disodium cromoglycate (cromolyn) inhibited this effect, including decrease of inflammatory cytokines, reduced microglial activation, inhibition of MAPK and AKT pathways, and repression of protein expression of histamine receptor 1 (H1R), histamine receptor 4 (H4R), protease-activated receptor 2 (PAR2), and toll-like receptor 4 (TLR4) in microglia.	Cromolyn Sodium	23-44	thymoma viral proto-oncogene 1	Mus musculus	179-182
26797518-5	2017	"Mast cell stabilizer" disodium cromoglycate (cromolyn) inhibited this effect, including decrease of inflammatory cytokines, reduced microglial activation, inhibition of MAPK and AKT pathways, and repression of protein expression of histamine receptor 1 (H1R), histamine receptor 4 (H4R), protease-activated receptor 2 (PAR2), and toll-like receptor 4 (TLR4) in microglia.	Cromolyn Sodium	23-44	histamine receptor H4	Mus musculus	255-286
26797518-5	2017	"Mast cell stabilizer" disodium cromoglycate (cromolyn) inhibited this effect, including decrease of inflammatory cytokines, reduced microglial activation, inhibition of MAPK and AKT pathways, and repression of protein expression of histamine receptor 1 (H1R), histamine receptor 4 (H4R), protease-activated receptor 2 (PAR2), and toll-like receptor 4 (TLR4) in microglia.	Cromolyn Sodium	23-44	coagulation factor II (thrombin) receptor-like 1	Mus musculus	289-318
26797518-5	2017	"Mast cell stabilizer" disodium cromoglycate (cromolyn) inhibited this effect, including decrease of inflammatory cytokines, reduced microglial activation, inhibition of MAPK and AKT pathways, and repression of protein expression of histamine receptor 1 (H1R), histamine receptor 4 (H4R), protease-activated receptor 2 (PAR2), and toll-like receptor 4 (TLR4) in microglia.	Cromolyn Sodium	23-44	coagulation factor II (thrombin) receptor-like 1	Mus musculus	320-324
26797518-5	2017	"Mast cell stabilizer" disodium cromoglycate (cromolyn) inhibited this effect, including decrease of inflammatory cytokines, reduced microglial activation, inhibition of MAPK and AKT pathways, and repression of protein expression of histamine receptor 1 (H1R), histamine receptor 4 (H4R), protease-activated receptor 2 (PAR2), and toll-like receptor 4 (TLR4) in microglia.	Cromolyn Sodium	23-44	toll-like receptor 4	Mus musculus	331-351
26797518-5	2017	"Mast cell stabilizer" disodium cromoglycate (cromolyn) inhibited this effect, including decrease of inflammatory cytokines, reduced microglial activation, inhibition of MAPK and AKT pathways, and repression of protein expression of histamine receptor 1 (H1R), histamine receptor 4 (H4R), protease-activated receptor 2 (PAR2), and toll-like receptor 4 (TLR4) in microglia.	Cromolyn Sodium	23-44	toll-like receptor 4	Mus musculus	353-357
26797518-5	2017	"Mast cell stabilizer" disodium cromoglycate (cromolyn) inhibited this effect, including decrease of inflammatory cytokines, reduced microglial activation, inhibition of MAPK and AKT pathways, and repression of protein expression of histamine receptor 1 (H1R), histamine receptor 4 (H4R), protease-activated receptor 2 (PAR2), and toll-like receptor 4 (TLR4) in microglia.	Cromolyn Sodium	46-54	thymoma viral proto-oncogene 1	Mus musculus	179-182
26797518-5	2017	"Mast cell stabilizer" disodium cromoglycate (cromolyn) inhibited this effect, including decrease of inflammatory cytokines, reduced microglial activation, inhibition of MAPK and AKT pathways, and repression of protein expression of histamine receptor 1 (H1R), histamine receptor 4 (H4R), protease-activated receptor 2 (PAR2), and toll-like receptor 4 (TLR4) in microglia.	Cromolyn Sodium	46-54	histamine receptor H4	Mus musculus	255-286
26797518-5	2017	"Mast cell stabilizer" disodium cromoglycate (cromolyn) inhibited this effect, including decrease of inflammatory cytokines, reduced microglial activation, inhibition of MAPK and AKT pathways, and repression of protein expression of histamine receptor 1 (H1R), histamine receptor 4 (H4R), protease-activated receptor 2 (PAR2), and toll-like receptor 4 (TLR4) in microglia.	Cromolyn Sodium	46-54	coagulation factor II (thrombin) receptor-like 1	Mus musculus	289-318
26797518-5	2017	"Mast cell stabilizer" disodium cromoglycate (cromolyn) inhibited this effect, including decrease of inflammatory cytokines, reduced microglial activation, inhibition of MAPK and AKT pathways, and repression of protein expression of histamine receptor 1 (H1R), histamine receptor 4 (H4R), protease-activated receptor 2 (PAR2), and toll-like receptor 4 (TLR4) in microglia.	Cromolyn Sodium	46-54	coagulation factor II (thrombin) receptor-like 1	Mus musculus	320-324
26797518-5	2017	"Mast cell stabilizer" disodium cromoglycate (cromolyn) inhibited this effect, including decrease of inflammatory cytokines, reduced microglial activation, inhibition of MAPK and AKT pathways, and repression of protein expression of histamine receptor 1 (H1R), histamine receptor 4 (H4R), protease-activated receptor 2 (PAR2), and toll-like receptor 4 (TLR4) in microglia.	Cromolyn Sodium	46-54	toll-like receptor 4	Mus musculus	331-351
26797518-5	2017	"Mast cell stabilizer" disodium cromoglycate (cromolyn) inhibited this effect, including decrease of inflammatory cytokines, reduced microglial activation, inhibition of MAPK and AKT pathways, and repression of protein expression of histamine receptor 1 (H1R), histamine receptor 4 (H4R), protease-activated receptor 2 (PAR2), and toll-like receptor 4 (TLR4) in microglia.	Cromolyn Sodium	46-54	toll-like receptor 4	Mus musculus	353-357
28002455-11	2016	We further treated URO-OVA mice with cromolyn, a mast cell membrane stabilizer, and found that cromolyn treatment reversed bladder inflammation and LUTD in the animal model.	Cromolyn Sodium	95-103	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	23-26
27289241-8	2016	Disodium cromolyn inhibited VEGF and PDGF-BB expression, and had no effects on EG VEGF expression between treated and non treated specimens in a mast cells free microenvironment.	Cromolyn Sodium	0-17	vascular endothelial growth factor A	Gallus gallus	28-32
26374606-8	2016	MPO-specific CD4(+) effector T cell proliferation was enhanced by co-culture with mast cells, but in the presence of disodium cromoglycate, proliferation was inhibited and IL-10 production was enhanced.	Cromolyn Sodium	117-138	myeloperoxidase	Mus musculus	0-3
27713021-3	2016	In this study we investigated whether disodium cromoglycate (DSCG), administered as a preventative treatment as in human therapy, could affect S1P effects on airways.	Cromolyn Sodium	38-59	sphingosine-1-phosphate receptor 1	Mus musculus	143-146
27713021-3	2016	In this study we investigated whether disodium cromoglycate (DSCG), administered as a preventative treatment as in human therapy, could affect S1P effects on airways.	Cromolyn Sodium	61-65	sphingosine-1-phosphate receptor 1	Mus musculus	143-146
27713021-4	2016	BALB/c mice, treated with DSCG, received subcutaneous administration of S1P.	Cromolyn Sodium	26-30	sphingosine-1-phosphate receptor 1	Mus musculus	72-75
27713021-6	2016	DSCG inhibited S1P-induced airway hyper-reactivity as well as pulmonary inflammation.	Cromolyn Sodium	0-4	sphingosine-1-phosphate receptor 1	Mus musculus	15-18
27713021-8	2016	IgE serum levels, prostaglandin D2, mucus production and IL-13 were also reduced when mice were pretreated with DSCG.	Cromolyn Sodium	112-116	interleukin 13	Mus musculus	57-62
27713021-11	2016	In conclusion we have shown that DSCG inhibits S1P-induced asthma like features in the mouse.	Cromolyn Sodium	33-37	sphingosine-1-phosphate receptor 1	Mus musculus	47-50
27310149-7	2016	However, cromolyn and ketotifen, membrane stabilizers, effectively inhibited the beta-hexosaminidase release induced by comp 1 or comp 4 by 39 and 45%, respectively.	Cromolyn Sodium	9-17	O-GlcNAcase	Homo sapiens	81-100
26374606-8	2016	MPO-specific CD4(+) effector T cell proliferation was enhanced by co-culture with mast cells, but in the presence of disodium cromoglycate, proliferation was inhibited and IL-10 production was enhanced.	Cromolyn Sodium	117-138	interleukin 10	Mus musculus	172-177
26374606-10	2016	Thus as a therapeutic, disodium cromoglycate may substantially enhance the regulatory role of mast cells in MPO-AAV.	Cromolyn Sodium	23-44	myeloperoxidase	Mus musculus	108-111
26597881-10	2016	MC supernatant fluids increased CCA histidine decarboxylase, vascular endothelial growth factor, and MC/EMT/ECM expression that decreased with pretreatment of cromolyn sodium.	Cromolyn Sodium	159-174	histidine decarboxylase	Homo sapiens	36-59
26597881-10	2016	MC supernatant fluids increased CCA histidine decarboxylase, vascular endothelial growth factor, and MC/EMT/ECM expression that decreased with pretreatment of cromolyn sodium.	Cromolyn Sodium	159-174	vascular endothelial growth factor A	Homo sapiens	61-95
26453959-10	2015	Furthermore, cromolyn treatment compromised the TGF-beta-induced epithelial mesenchyme transition and replicative senescence rate of hepatocytes, which are generally associated with fibrogenesis.	Cromolyn Sodium	13-21	transforming growth factor beta 1	Homo sapiens	48-56
25497346-9	2015	In rat, alarin-LI was detected in only a minority of cranial autonomic ganglia (CIL: 3.5%; PPG: 0.4%; SCG: 1.9%; TRI: 1%).	Cromolyn Sodium	102-105	galanin like peptide	Homo sapiens	8-14
26350008-11	2015	CONCLUSION: Sodium cromoglycate can stabilize mast cells from degranulation, which may relieve the clinical symptoms of endometriosis by reducing TNF-alpha and tryptase levels.	Cromolyn Sodium	12-31	tumor necrosis factor	Rattus norvegicus	146-155
26350008-11	2015	CONCLUSION: Sodium cromoglycate can stabilize mast cells from degranulation, which may relieve the clinical symptoms of endometriosis by reducing TNF-alpha and tryptase levels.	Cromolyn Sodium	12-31	tryptase alpha/beta 1	Rattus norvegicus	160-168
26052828-10	2015	Four-day hypoxia led to changes in distribution of toluidine blue-detected and MMP-13 positive periarterial mast cells; this redistribution was also influenced by the administration of sodium cromoglycate.	Cromolyn Sodium	185-204	matrix metallopeptidase 13	Rattus norvegicus	79-85
25682766-6	2015	Lomusol was also able to induce significant reduction in eosinophil cationic protein (ECP) levels in nasal secretions without altering the percentage of eosinophil influx in nasal cytology.	Cromolyn Sodium	0-7	ribonuclease A family member 3	Homo sapiens	57-84
25682766-6	2015	Lomusol was also able to induce significant reduction in eosinophil cationic protein (ECP) levels in nasal secretions without altering the percentage of eosinophil influx in nasal cytology.	Cromolyn Sodium	0-7	ribonuclease A family member 3	Homo sapiens	86-89
23368763-0	2014	Evaluation of naproxen and cromolyn activities against cancer cells viability, proliferation, apoptosis, p53 and gene expression of survivin and caspase-3.	Cromolyn Sodium	27-35	tumor protein p53	Homo sapiens	105-108
25468905-2	2015	Here we demonstrate that cromolyn sodium (disodium cromoglycate), a Food and Drug Administration-approved drug already in use for the treatment of asthma, efficiently inhibits the aggregation of Abeta monomers into higher-order oligomers and fibrils in vitro without affecting Abeta production.	Cromolyn Sodium	25-40	amyloid beta precursor protein	Homo sapiens	195-200
25365204-14	2014	In vivo, cromolyn treatment decreased BDL-induced: (i) IBDM, MC number, and biliary proliferation; (ii) HDC and MC marker expression; and (iii) HA levels.	Cromolyn Sodium	9-17	histidine decarboxylase	Rattus norvegicus	104-107
25365204-16	2014	In vitro, cromolyn decreased HA release and chymase and tryptase expression in MCs but not in cholangiocytes.	Cromolyn Sodium	10-18	chymase 1	Rattus norvegicus	44-51
25365204-16	2014	In vitro, cromolyn decreased HA release and chymase and tryptase expression in MCs but not in cholangiocytes.	Cromolyn Sodium	10-18	tryptase alpha/beta 1	Rattus norvegicus	56-64
25147231-8	2014	The mast cell stabilizers cromolyn and doxantrazole suppressed release of protease II and histamine when evoked by SP, CGRP, capsaicin, A23187, electrical stimulation of afferents, or compound 48/80.	Cromolyn Sodium	26-34	calcitonin related polypeptide alpha	Homo sapiens	119-123
25468905-2	2015	Here we demonstrate that cromolyn sodium (disodium cromoglycate), a Food and Drug Administration-approved drug already in use for the treatment of asthma, efficiently inhibits the aggregation of Abeta monomers into higher-order oligomers and fibrils in vitro without affecting Abeta production.	Cromolyn Sodium	25-40	amyloid beta precursor protein	Homo sapiens	277-282
25468905-2	2015	Here we demonstrate that cromolyn sodium (disodium cromoglycate), a Food and Drug Administration-approved drug already in use for the treatment of asthma, efficiently inhibits the aggregation of Abeta monomers into higher-order oligomers and fibrils in vitro without affecting Abeta production.	Cromolyn Sodium	42-63	amyloid beta precursor protein	Homo sapiens	195-200
25468905-2	2015	Here we demonstrate that cromolyn sodium (disodium cromoglycate), a Food and Drug Administration-approved drug already in use for the treatment of asthma, efficiently inhibits the aggregation of Abeta monomers into higher-order oligomers and fibrils in vitro without affecting Abeta production.	Cromolyn Sodium	42-63	amyloid beta precursor protein	Homo sapiens	277-282
25468905-3	2015	In vivo, the levels of soluble Abeta are decreased by over 50% after only 1 week of daily intraperitoneally administered cromolyn sodium.	Cromolyn Sodium	121-136	amyloid beta precursor protein	Homo sapiens	31-36
25468905-5	2015	These data suggest a clear effect of a peripherally administered, Food and Drug Administration-approved medication on Abeta economy, supporting further investigation of the potential long-term efficacy of cromolyn sodium in Alzheimer disease.	Cromolyn Sodium	205-220	amyloid beta precursor protein	Homo sapiens	118-123
23368763-0	2014	Evaluation of naproxen and cromolyn activities against cancer cells viability, proliferation, apoptosis, p53 and gene expression of survivin and caspase-3.	Cromolyn Sodium	27-35	caspase 3	Homo sapiens	145-154
24169849-10	2014	Combining tPA with high-dose cromoglycate mitigated hemispheric expansion (7.4+-1.7 versus 14.5+-5.0%; P=0.01), improved neurologic outcome (P<0.001) and decreased mortality (1/10; P<0.05) compared with tPA alone.	Cromolyn Sodium	29-41	plasminogen activator, tissue type	Rattus norvegicus	209-212
24465509-6	2014	Mice treated with DSCG had significantly reduced levels of the inflammatory cytokines IL-1alpha, IL-1beta, and CXCL1.	Cromolyn Sodium	18-22	interleukin 1 alpha	Mus musculus	86-95
24465509-6	2014	Mice treated with DSCG had significantly reduced levels of the inflammatory cytokines IL-1alpha, IL-1beta, and CXCL1.	Cromolyn Sodium	18-22	interleukin 1 beta	Mus musculus	97-105
24465509-6	2014	Mice treated with DSCG had significantly reduced levels of the inflammatory cytokines IL-1alpha, IL-1beta, and CXCL1.	Cromolyn Sodium	18-22	chemokine (C-X-C motif) ligand 1	Mus musculus	111-116
24142033-0	2014	Anti-CD200R2, anti-IL-9, anti-IL-35, or anti-TGF-beta abolishes increased graft survival and Treg induction induced in cromolyn-treated CD200R1KO.CD200tg mice.	Cromolyn Sodium	119-127	Cd200 receptor 2	Mus musculus	5-12
24142033-0	2014	Anti-CD200R2, anti-IL-9, anti-IL-35, or anti-TGF-beta abolishes increased graft survival and Treg induction induced in cromolyn-treated CD200R1KO.CD200tg mice.	Cromolyn Sodium	119-127	interleukin 9	Mus musculus	19-23
24142033-0	2014	Anti-CD200R2, anti-IL-9, anti-IL-35, or anti-TGF-beta abolishes increased graft survival and Treg induction induced in cromolyn-treated CD200R1KO.CD200tg mice.	Cromolyn Sodium	119-127	transforming growth factor, beta 1	Mus musculus	45-53
24142033-7	2014	RESULTS: Decreased MC degranulation and increased graft Foxp3 Treg infiltration/survival occurred in CD200 mice and in CD200-treated control mice or CD200R1KO.CD200 mice receiving cromoglycate.	Cromolyn Sodium	180-192	forkhead box P3	Mus musculus	56-61
24142033-7	2014	RESULTS: Decreased MC degranulation and increased graft Foxp3 Treg infiltration/survival occurred in CD200 mice and in CD200-treated control mice or CD200R1KO.CD200 mice receiving cromoglycate.	Cromolyn Sodium	180-192	CD200 antigen	Mus musculus	119-124
24142033-7	2014	RESULTS: Decreased MC degranulation and increased graft Foxp3 Treg infiltration/survival occurred in CD200 mice and in CD200-treated control mice or CD200R1KO.CD200 mice receiving cromoglycate.	Cromolyn Sodium	180-192	CD200 antigen	Mus musculus	119-124
24265375-0	2013	Cromolyn sodium for insulin-induced lipoatrophy: old drug, new use.	Cromolyn Sodium	0-15	insulin	Homo sapiens	20-27
24483474-7	2013	From these measurements, the helical twisting power for L-alanine is found to be (1.1+-0.4)x10(-2) mum(-1) wt%(-1) for 15 wt% disodium cromoglycate.	Cromolyn Sodium	126-147	PWWP domain containing 3A, DNA repair factor	Homo sapiens	99-105
23864254-9	2013	In conclusion, administration of CS after reperfusion, but not prior to ischemia, attenuates IIRI by downregulating ET-1 and suppressing sustained MC activation.	Cromolyn Sodium	33-35	endothelin 1	Mus musculus	116-120
23784744-0	2013	Naproxen and cromolyn as new glycogen synthase kinase 3beta inhibitors for amelioration of diabetes and obesity: an investigation by docking simulation and subsequent in vitro/in vivo biochemical evaluation.	Cromolyn Sodium	13-21	glycogen synthase kinase 3 beta	Mus musculus	29-59
23784744-1	2013	Naproxen and cromolyn were investigated as new inhibitors of glycogen synthase kinase-3beta (GSK-3beta) in an attempt to explain their hypoglycemic properties.	Cromolyn Sodium	13-21	glycogen synthase kinase 3 beta	Mus musculus	61-91
23784744-1	2013	Naproxen and cromolyn were investigated as new inhibitors of glycogen synthase kinase-3beta (GSK-3beta) in an attempt to explain their hypoglycemic properties.	Cromolyn Sodium	13-21	glycogen synthase kinase 3 beta	Mus musculus	93-102
23784744-3	2013	Both drugs not only were optimally fitted within a GSK-3beta binding pocket via several attractive interactions with key amino acids but also exhibited potent in vitro enzymatic inhibitory activities of IC50 1.5 and 2.0 microM for naproxen and cromolyn, respectively.	Cromolyn Sodium	244-252	glycogen synthase kinase 3 beta	Mus musculus	51-60
23784744-6	2013	It can be concluded that naproxen and cromolyn are novel GSK-3beta inhibitors and can help in management of diabetes and obesity.	Cromolyn Sodium	38-46	glycogen synthase kinase 3 beta	Mus musculus	57-66
22906983-3	2012	We confirmed that cromolyn (at 10 mg/kg in vivo or 10-100 muM in vitro) can inhibit IgE-dependent mast cell activation in rats in vivo (measuring Evans blue extravasation in passive cutaneous anaphylaxis (PCA) and increases in plasma histamine in passive systemic anaphylaxis (PSA)) and in vitro (measuring peritoneal mast cell (PMC) beta-hexosaminidase release and prostaglandin D(2) synthesis).	Cromolyn Sodium	18-26	O-GlcNAcase	Rattus norvegicus	334-353
23880180-7	2013	In aortic arches, however, cromolyn treatment significantly reduced lesion contents of Mac-3(+) macrophages, CD4(+) T cells, activated MCs, and lesion cell proliferation.	Cromolyn Sodium	27-35	lysosomal-associated membrane protein 2	Mus musculus	87-92
23880180-7	2013	In aortic arches, however, cromolyn treatment significantly reduced lesion contents of Mac-3(+) macrophages, CD4(+) T cells, activated MCs, and lesion cell proliferation.	Cromolyn Sodium	27-35	CD4 antigen	Mus musculus	109-112
23303403-1	2013	We have previously shown that the antiallergic drug cromolyn blocks S100P interaction with its receptor receptor for advanced glycation end product (RAGE) and improves gemcitabine effectiveness in pancreatic ductal adenocarcinoma (PDAC).	Cromolyn Sodium	52-60	advanced glycosylation end product-specific receptor	Mus musculus	104-147
23303403-1	2013	We have previously shown that the antiallergic drug cromolyn blocks S100P interaction with its receptor receptor for advanced glycation end product (RAGE) and improves gemcitabine effectiveness in pancreatic ductal adenocarcinoma (PDAC).	Cromolyn Sodium	52-60	advanced glycosylation end product-specific receptor	Mus musculus	149-153
23249992-10	2013	Cromoglycate fully prevented the tryptase release in the perfusate and the compound 48/80 substantially reduced tryptase activity in the incised tissue.	Cromolyn Sodium	0-12	tryptase alpha/beta 1	Mus musculus	33-41
23071133-8	2013	C5a most likely exerts its function via mast cell activation since the mast cell inhibitor cromolyn totally blocked C5a-enhanced vein graft disease.	Cromolyn Sodium	91-99	hemolytic complement	Mus musculus	0-3
23071133-8	2013	C5a most likely exerts its function via mast cell activation since the mast cell inhibitor cromolyn totally blocked C5a-enhanced vein graft disease.	Cromolyn Sodium	91-99	hemolytic complement	Mus musculus	116-119
24369442-4	2013	Sevoflurane preconditioning dramatically attenuated the previous IIR-induced alterations except MC counts, tryptase, and beta-hexosaminidase which were significantly reduced by CS treatment.	Cromolyn Sodium	177-179	tryptase alpha/beta 1	Rattus norvegicus	107-115
24369442-4	2013	Sevoflurane preconditioning dramatically attenuated the previous IIR-induced alterations except MC counts, tryptase, and beta-hexosaminidase which were significantly reduced by CS treatment.	Cromolyn Sodium	177-179	O-GlcNAcase	Rattus norvegicus	121-140
23290058-0	2012	[Effects of cromolyn sodium on intestinal ischemia-reperfusion injury by inhibiting PAR-2 expression in rats].	Cromolyn Sodium	12-27	F2R like trypsin receptor 1	Rattus norvegicus	84-89
23290058-1	2012	OBJECTIVE: To explore the effects of cromolyn sodium (CS) on intestinal ischemia-reperfusion (IIR) and its relationship with mast cell activation and protease-activated receptor 2 (PAR-2) expression.	Cromolyn Sodium	37-52	F2R like trypsin receptor 1	Rattus norvegicus	150-179
23290058-1	2012	OBJECTIVE: To explore the effects of cromolyn sodium (CS) on intestinal ischemia-reperfusion (IIR) and its relationship with mast cell activation and protease-activated receptor 2 (PAR-2) expression.	Cromolyn Sodium	37-52	F2R like trypsin receptor 1	Rattus norvegicus	181-186
23290058-1	2012	OBJECTIVE: To explore the effects of cromolyn sodium (CS) on intestinal ischemia-reperfusion (IIR) and its relationship with mast cell activation and protease-activated receptor 2 (PAR-2) expression.	Cromolyn Sodium	54-56	F2R like trypsin receptor 1	Rattus norvegicus	150-179
23290058-10	2012	CONCLUSION: Cromolyn sodium may reduce IIR injury by stabilizing mast cell membrane and inhibiting the expressions of tryptase and PAR-2.	Cromolyn Sodium	12-27	tryptase alpha/beta 1	Rattus norvegicus	118-126
23290058-10	2012	CONCLUSION: Cromolyn sodium may reduce IIR injury by stabilizing mast cell membrane and inhibiting the expressions of tryptase and PAR-2.	Cromolyn Sodium	12-27	F2R like trypsin receptor 1	Rattus norvegicus	131-136
22906983-7	2012	At 100 mg/kg, a concentration 10 times higher than that which inhibited PSA in rats, cromolyn significantly inhibited the increases in plasma concentrations of mouse mast cell protease-1 (but not of histamine) during PSA, but had no effect on the reduction in body temperature in this setting.	Cromolyn Sodium	85-93	mast cell protease 1	Mus musculus	166-186
22906983-8	2012	Moreover, this concentration of cromolyn (100 mg/kg) also inhibited LPS-induced TNF production in genetically mast cell-deficient C57BL/6-Kit(W-sh/W-sh) mice in vivo.	Cromolyn Sodium	32-40	tumor necrosis factor	Mus musculus	80-83
21819958-2	2011	In this study, we treated infected CBA mice with cromolyn, an MC stabilizer, and observed much greater parasitemia and interferon-gamma levels, higher mortality, myocarditis, and cardiac damage.	Cromolyn Sodium	49-57	interferon gamma	Mus musculus	119-135
22414385-8	2012	The involvement of HQ-induced TNF secretion in trachea mast cell degranulation was also demonstrated by the partial reversion of tracheal hyperresponsiveness in sodium cromoglicate-treated animals, and the in vivo HQ-exposure-induced degranulation of trachea connective tissue and mucosal mast cells, which was reversed by CPZ treatment.	Cromolyn Sodium	161-180	tumor necrosis factor	Mus musculus	30-33
22493240-4	2012	MC-deficient mouse strains and mice treated with the MC stabilizing agent cromolyn sodium had dramatically reduced Th2 priming and type 2 cytokine production and harbored increased parasite burdens following infection with gastrointestinal helminths (Heligmosomoides polygyrus bakeri and Trichuris muris).	Cromolyn Sodium	74-89	heart and neural crest derivatives expressed 2	Mus musculus	115-118
22470478-9	2012	However, Que is more effective than cromolyn in inhibiting IL-8 and TNF release from LAD2 mast cells stimulated by SP.	Cromolyn Sodium	36-44	C-X-C motif chemokine ligand 8	Homo sapiens	59-63
22470478-9	2012	However, Que is more effective than cromolyn in inhibiting IL-8 and TNF release from LAD2 mast cells stimulated by SP.	Cromolyn Sodium	36-44	tumor necrosis factor	Homo sapiens	68-71
21586281-6	2011	One muM cromoglycate partially inhibited these two responses.	Cromolyn Sodium	8-20	latexin	Homo sapiens	4-7
22492684-9	2012	Cromolyn, a mast cell inhibitor attenuated mast cell degranulation as well as IL-4 mRNA expression and cardiac fibrosis without affecting blood pressure.	Cromolyn Sodium	0-8	interleukin 4	Mus musculus	78-82
22492684-10	2012	Treatment with Cromolyn also reduced interstitial fibroblasts and macrophages in regions of developing fibrosis as well MCP-1 expression.	Cromolyn Sodium	15-23	chemokine (C-C motif) ligand 2	Mus musculus	120-125
21622682-7	2011	Ang I + CMP48/80 induced enhanced leucocyte adhesion that was attenuated by losartan, enalapril, enalapril + chymostatin, and cromolyn (a mast cell stabilizer).	Cromolyn Sodium	126-134	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	0-5
21678472-11	2011	Immunohistochemical analysis revealed nerves expressing the stem cell markers nanog and Klf4, as well as the osteoblast marker osterix, after BMP2 induction, in mice treated with cromolyn.	Cromolyn Sodium	179-187	Kruppel-like factor 4 (gut)	Mus musculus	88-92
21678472-11	2011	Immunohistochemical analysis revealed nerves expressing the stem cell markers nanog and Klf4, as well as the osteoblast marker osterix, after BMP2 induction, in mice treated with cromolyn.	Cromolyn Sodium	179-187	bone morphogenetic protein 2	Mus musculus	142-146
21385340-0	2011	The effects of topical sodium cromoglicate on itch and flare in human skin induced by intradermal histamine: a randomised double-blind vehicle controlled intra-subject design trial.	Cromolyn Sodium	23-42	itchy E3 ubiquitin protein ligase	Homo sapiens	46-50
21385340-2	2011	Sodium cromoglicate (SCG), a chromone developed for the treatment of allergic disease has been shown to reduce the severity of itch when applied topically to subjects with atopic dermatitis.	Cromolyn Sodium	0-19	itchy E3 ubiquitin protein ligase	Homo sapiens	127-131
21385340-2	2011	Sodium cromoglicate (SCG), a chromone developed for the treatment of allergic disease has been shown to reduce the severity of itch when applied topically to subjects with atopic dermatitis.	Cromolyn Sodium	21-24	itchy E3 ubiquitin protein ligase	Homo sapiens	127-131
21385340-3	2011	The aim of this study was to investigate whether topical sodium cromoglicate can reduce the severity of itch induced by intradermal histamine.	Cromolyn Sodium	57-76	itchy E3 ubiquitin protein ligase	Homo sapiens	104-108
19702783-10	2009	Increased macrophage numbers enhanced, while cromolyn sodium (mast cell stabilizer) diminished, LIX/CXCL5-induced neutrophil recruitment.	Cromolyn Sodium	45-60	chemokine (C-X-C motif) ligand 5	Mus musculus	96-99
21437947-0	2011	Sodium cromolyn reduces expression of CTGF, ADAMTS1, and TIMP3 and modulates post-injury patellar tendon morphology.	Cromolyn Sodium	0-15	cellular communication network factor 2	Mus musculus	38-42
21437947-0	2011	Sodium cromolyn reduces expression of CTGF, ADAMTS1, and TIMP3 and modulates post-injury patellar tendon morphology.	Cromolyn Sodium	0-15	a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 1	Mus musculus	44-51
21437947-0	2011	Sodium cromolyn reduces expression of CTGF, ADAMTS1, and TIMP3 and modulates post-injury patellar tendon morphology.	Cromolyn Sodium	0-15	tissue inhibitor of metalloproteinase 3	Mus musculus	57-62
20579383-4	2010	In this case we report how in a mastocytosis patient being treated with H1 and H2 antihistamines, and oral sodium cromoglicate, the addition of inhaled sodium cromoglicate resulted in further improvement.	Cromolyn Sodium	152-171	H1.5 linker histone, cluster member	Homo sapiens	72-81
19702783-10	2009	Increased macrophage numbers enhanced, while cromolyn sodium (mast cell stabilizer) diminished, LIX/CXCL5-induced neutrophil recruitment.	Cromolyn Sodium	45-60	chemokine (C-X-C motif) ligand 5	Mus musculus	100-105
19422371-9	2009	In sham animals ET-1 and compound 48/80 both induced mast cell degranulation (P < 0.001), an effect which was abolished by DSCG, confirming their ability to induce degranulation of mast cells.	Cromolyn Sodium	126-130	endothelin 1	Rattus norvegicus	16-20
19428336-4	2009	When administered alone, cromoglycate or nedocromil had little effect on this pathway however, in the presence of a fixed sub-maximal concentration of GCs, increasing amounts of the cromoglycate-like drugs caused a striking concentration-dependent enhancement of Anx-A1 and PKCalpha/beta phosphorylation, membrane recruitment and Anx-A1 release from cells resulting in greatly enhanced inhibition of TxB(2) generation.	Cromolyn Sodium	182-194	annexin A1	Homo sapiens	263-269
19428336-4	2009	When administered alone, cromoglycate or nedocromil had little effect on this pathway however, in the presence of a fixed sub-maximal concentration of GCs, increasing amounts of the cromoglycate-like drugs caused a striking concentration-dependent enhancement of Anx-A1 and PKCalpha/beta phosphorylation, membrane recruitment and Anx-A1 release from cells resulting in greatly enhanced inhibition of TxB(2) generation.	Cromolyn Sodium	182-194	protein kinase C alpha	Homo sapiens	274-287
19428336-4	2009	When administered alone, cromoglycate or nedocromil had little effect on this pathway however, in the presence of a fixed sub-maximal concentration of GCs, increasing amounts of the cromoglycate-like drugs caused a striking concentration-dependent enhancement of Anx-A1 and PKCalpha/beta phosphorylation, membrane recruitment and Anx-A1 release from cells resulting in greatly enhanced inhibition of TxB(2) generation.	Cromolyn Sodium	182-194	annexin A1	Homo sapiens	330-336
19428336-7	2009	We conclude that stimulation by the cromoglycate-like drugs of intracellular Anx-A1 trafficking and release (hence inhibition of eicosanoid release) is secondary to inhibition of a phosphatase PP2A (phosphoprotein phosphatase; EC 3.1.3.16), which probably forms part of a control loop to limit Anx-A1 release.	Cromolyn Sodium	36-48	annexin A1	Homo sapiens	77-83
19428336-7	2009	We conclude that stimulation by the cromoglycate-like drugs of intracellular Anx-A1 trafficking and release (hence inhibition of eicosanoid release) is secondary to inhibition of a phosphatase PP2A (phosphoprotein phosphatase; EC 3.1.3.16), which probably forms part of a control loop to limit Anx-A1 release.	Cromolyn Sodium	36-48	protein phosphatase 2 phosphatase activator	Homo sapiens	193-197
19428336-7	2009	We conclude that stimulation by the cromoglycate-like drugs of intracellular Anx-A1 trafficking and release (hence inhibition of eicosanoid release) is secondary to inhibition of a phosphatase PP2A (phosphoprotein phosphatase; EC 3.1.3.16), which probably forms part of a control loop to limit Anx-A1 release.	Cromolyn Sodium	36-48	annexin A1	Homo sapiens	294-300
19328828-5	2009	Mast cell stabilization with cromolyn blocked the Compound 48/80-induced decrease in ANP release.	Cromolyn Sodium	29-37	natriuretic peptides A	Oryctolagus cuniculus	85-88
19428336-0	2009	Cromoglycate drugs suppress eicosanoid generation in U937 cells by promoting the release of Anx-A1.	Cromolyn Sodium	0-12	annexin A1	Homo sapiens	92-98
19428336-1	2009	Using biochemical, epifluorescence and electron microscopic techniques in a U937 model system, we investigated the effect of anti-allergic drugs di-sodium cromoglycate and sodium nedocromil on the trafficking and release of the anti-inflammatory protein Annexin-A1 (Anx-A1) when this was triggered by glucocorticoid (GC) treatment.	Cromolyn Sodium	145-167	annexin A1	Homo sapiens	254-264